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Abstract 
Diseases can occur due to genetic changes that alter the normal function of genes. These 
alterations may be either inherited, thus present in every cell of an individual at birth, or 
acquired somatically during lifetime. In this thesis, a combination of genome-wide 
measurement technologies, a unique national registry of all cancer cases, and sophisticated 
data analysis methods were utilized to study the genetic background of human diseases. Aims 
of this thesis work were to efficiently analyze large quantities of epidemiological and 
molecular data, and to characterize new susceptibility conditions and genetic causes of human 
diseases. 
First, unknown genetic basis of right atrial isomerism (RAI) was studied in a previously 
reported Finnish family with five affected siblings and healthy parents. RAI is a heterotaxy 
syndrome with disturbances in the left-right axis development resulting in complex heart 
malformations and abnormal lateralization of other thoracic and abdominal organs. 
Heterotaxy syndromes are associated with a few known allelic variants in humans, although 
studies with model organisms have identified several genes involved in the early regulation of 
laterality. Linkage analysis and candidate-gene approach followed by sequencing revealed 
two truncating mutations in GDF1 segregating with the RAI phenotype in an autosomal 
recessive manner. This finding, supported by the similar phenotype of laterality defects in 
Gdf1 knockout mice, provides evidence that RAI can be recessively inherited with GDF1 as 
the causative gene. 
Second, six clinically well-characterized patients with severe intellectual disability (ID) of 
unknown etiology were studied by genetic mapping and whole-genome sequencing (WGS) 
analysis. ID is a genetically extremely heterogeneous condition where many autosomal 
recessive genes are yet to be identified. In this study, autosomal recessive inheritance of 
severe ID was confirmed by extensive genealogy, and by linkage analysis showing the 
logarithm of odds score of 11 for a homozygous region at 3p22.1-3p21.1. The WGS data 
revealed three candidate genes, TKT, P4HTM and USP4, with potentially protein damaging 
sequence changes within the locus. The variants were present in heterozygous form with 0.3-
0.7% allele frequencies in population-matched controls from Northern Finland. This study 
facilitates clinical and molecular diagnosis of similar patients and further research on the role 
of the genes in the development of severe ID. 
Third, the molecular genetic landscape of uterine leioymomas was studied utilizing the most 
recent genome-wide technologies. Uterine leiomyomas are benign tumors that affect 
approximately three-quarters of all women and may cause severe symptoms including 
abdominal pain and excessive uterine bleeding. We sequenced the genomes of 38 leiomyomas 
and corresponding myometrium tissues from 30 women, and performed whole-transcriptome 
profiling of the same tissue specimes. Abundant complex chromosomal rearrangement events 
resembling the recently described chromothripsis phenomenon were detected in leiomyomas. 
The events had created leiomyoma-specific driver changes, and occurred sequentially in some 
tumors. Four mutually exclusive molecular pathways driven by alterations of MED12, FH, 
HMGA2/HMGA1 or COL4A5/COL4A6 were identified. The clonal origin of multiple separate 
tumors was proven by sequence analysis. The molecular genetic characterization of uterine 
leiomyomas will hopefully lead to better understanding of tumor growth and personalized 
treatment of patients. 
Fourth, a systematic search for familial aggregation of all types of cancer was performed to 
identify new tumor susceptibility phenotypes and families. Traditionally, information on 
8 
 
family relations is a prerequisite for familiality studies. We employed the entire population 
based data in the Finnish Cancer Registry and clustered 878,593 patients according to family 
name at birth, municipality of birth and tumor type. To estimate the rate of familial 
occurrence, a cluster score was calculated for all tumor types producing significant clusters. 
Known cancer predisposition syndromes displayed the highest cluster scores, and some 
phenotypes with largely unknown genetic background, such as Kaposi sarcoma (KS), were 
also highlighted. Population records verified majority of the clustered KS patients as true 
relatives, providing further evidence that the clustering works well in estimating familiality. 
The effort described in this study enabled identification of families suitable for a succeeding 
research on genetic basis of novel tumor predisposition phenotypes.  
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1 Introduction 
Many diseases have a genetic cause, which can be either inherited or acquired over lifetime. 
Vast majority of diseases are complex, arising as a combination of genetic, environmental and 
life-style factors. When the inheritance of the disease is clear and caused by a single gene, 
such as in many congenital diseases, the pattern of inheritance can be deduced from 
multigenerational families. Mendelian patterns of inheritance include dominant and recessive 
inheritance. Complex diseases do not follow simple Mendelian patterns of inheritance, 
although a genetic susceptibility to develop the disease may be inherited. Cancer is an 
example of a complex disease that arises from mutations that accumulate somatically in the 
descendants of a cell over time, causing tumor growth in a specific organ of the body. 
Identification of novel genetic causes of diseases is empowered by the completion of the 
human genome sequencing project and the advent of next-generation sequencing technologies. 
If a disease seems to run in families and sample materials are available from multiple affected 
individuals, genetic mapping followed by sequencing of candidate regions can be used to 
determine the disease-causing genetic changes. Genetic mapping examines co-segregation of 
genetic markers and disease in a family pedigree. Within the last couple of years, whole-
genome sequencing has become more affordable allowing genome-wide comparison of 
genetic changes in multiple samples, and discovery of structural variants and complex 
chromosomal changes, which could not have been detected with traditional molecular 
approaches. The new sequencing technologies have increased our knowledge of the amount 
and type of variation in human populations and genetic diseases. 
In this thesis work, microarrays were used to measure genome-wide genotypes of 
approximately 300,000 to 2 million single nucleotide polymorphisms or transcript abundance 
of over 35,000 genes. Next-generation sequencing technologies were used to produce millions 
of short sequencing reads from individual genomes which were analyzed for alterations by 
comparing them to the 3 billion base pairs in the human reference genome. Furthermore, over 
one million patient records in the Finnish Cancer Registry were analyzed for familial 
aggregation to estimate heritability of various tumor types. Without computational data 
analysis and integration methods, biological interpretation of these large-scale data would be 
unfeasible.  
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2 Review of the literature 
2.1 Human genome 
Hereditary information is encoded in sequences of deoxyribonucleic acid (DNA) molecules 
organized in 46 chromosomes in the cell nucleus, and in mitochondrial DNA. DNA molecule 
units, nucleotides, are composed of sugar and phosphate backbones, and of four different 
nucleobases, one in each nucleotide. The bases are grouped into purines [adenine (A) and 
guanine (G)] and pyrimidines [cytosine (C) and thymine (T)]. Purines and pyrimidines form 
pairs in the double-strand helix structure of DNA resolved by Watson and Crick in 1953 
(Watson and Crick, 1953). 
2.1.1 Human reference genome 
The human reference genome is used to describe the consensus of the base pair-level 
composition of the haploid genome of the 22 autosomes, the X and Y chromosomes, and the 
mitochondrial DNA. The total length of the human reference genome is approximately 3 
billion base pairs (bp) and more than 99% of this is shared between individuals (The Human 
Genome Project, 2014), although more and more variation has been detected in individual 
genomes as compared to the reference genome by utilizing new genome-wide technologies 
(Pang et al., 2010). 
Completion of the sequencing of the human genome was celebrated in April 2003 when the 
Build 34 version of the human reference genome was published by the International Human 
Genome Sequencing Consortium (The Human Genome Project, 2014). The aim of the project 
was to identify the nucleotide composition of the euchromatic genome with 99.99% accuracy 
and to make this information publicly available. The euchromatic portion of the human 
genome was estimated to consist of 20,000–25,000 protein coding genes (International 
Human Genome Sequencing Consortium, 2004). Since 2003, much work has been done to fill 
in gaps and refine complex sequences to produce a better consensus representation of the 
human genome.  
The human reference genome version used in most parts of this thesis was produced by the 
Genome Reference Consortium (GRC) in 2009 (Build 37). The GRC is a collaborative effort 
of many research institutes, and it aims to produce a high quality reference assembly where 
any sequences longer than 500 bp are positioned into a chromosome context. The reference 
assembly produced by the GRC represents chromosomes as well as unlocalized, unplaced and 
alternate loci sequences of the human genome (Church et al., 2011). These improvements in 
the reference assembly are needed to better account for structural diversity in human 
populations and to allow more accurate next-generation sequencing analysis, as described in 
section 2.3.4. 
2.1.2 DNA sequence variation in human populations 
Single nucleotide variation (SNV) is the most common variation in the human genome; it 
occurs when a single nucleotide in the studied DNA differs from the reference genome. The 
National Center for Biotechnology Information (NCBI) maintains a central repository, the 
Database of Short Genetic Variation (dbSNP) for single base nucleotide substitutions, for 
short multi-base insertions and deletions (indels), and for microsatellite repeats in the human 
genome as compared to the reference assembly (Kitts et al., 2013). Each variation type per 
location in the genome is identified with a “Reference SNP” (rs) identifier. The advent of 
next-generation sequencing (NGS) has increased the number of rs variants from 23,653,737 in 
dbSNP build 131 (Mar 25, 2010) to 62,676,337 in build 138 (April 25, 2013). dbSNP 
manages data on the sequence context of the variant, the frequency of the polymorphism in 
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populations and all the relevant experimental information from the submitter, while databases 
such as NCBI’s ClinVar database, The Human Gene Mutation Database (HGMD) (Stenson et 
al., 2013) and Online Mendelian Inheritance in Man (OMIM) (Hamosh et al., 2005) store 
clinical significance information of variants found in patient samples.  
The International HapMap Project was started in 2002 in order to identify common single 
nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) >5% in human 
populations (International HapMap Consortium, 2003). More than one million common SNPs 
were genotyped in the initial set of 270 samples from individuals with African, Asian and 
European ancestry, including 60 parent-offspring trios (International HapMap Consortium, 
2005). Additional SNPs and seven more admixed populations residing in the US were 
genotyped in the later phases of the project (International HapMap 3 Consortium et al., 2010; 
International HapMap Consortium et al., 2007). One major goal of the HapMap Project was 
to identify statistically related SNPs and to create all unique haplotypes across the genotyped 
individuals (International HapMap Consortium, 2005). Recombination rates as well as 
distribution information within and between populations have also been provided for the 
genotyped SNPs and haplotypes by the HapMap project. 
Database of Genomic Variants (DGV) was established after first reports of high prevalence of 
copy number variations (CNVs) (about 100 kb and greater) in the genomes of healthy 
individuals (Macdonald et al., 2014; Sebat et al., 2004). The objective of the database is to 
provide numerous types of structural variations (SVs), including copy number gains, 
duplications, insertions, inversions and complex variants observed in healthy control samples. 
The variant data in the database comes mostly from microarrays (44%) and sequencing 
studies (53%), and it is enriched for deletions and copy number losses (70%) (Macdonald et 
al., 2014). Mapping the full spectrum of variation in an individual genome (J Craig Venter's 
DNA) revealed that approximately 1.2% of this genome is encompassed by indels and CNVs, 
0.3% by inversions and 0.1% by SNPs. In the study of the Venter genome, the reported SVs 
affected 4,867 genes, some of which were linked to human disease phenotypes (Pang et al., 
2010).  
At the time NGS technologies became available in 2008, the 1000 Genomes project was 
launched (1000 Genomes Project Consortium et al., 2010). The aim of the project was to 
develop methodologies to cost-effectively and accurately detect majority of single nucleotide 
and structural variants with frequencies of at least 1% in 2,500 individuals from the five major 
population groups (European, East Asian, South Asian, West African and American ancestry). 
In 2012, an integrated map of SNPs, indels and larger deletions was published from the 
genomes of 1,092 individuals by using NGS sequencing and SNP genotyping assays. These 
data showed that variants with the frequency of at least 10% across all individuals were 
present in each of the populations studied, whereas low-frequency variants (<5%), which tend 
to be recent, differentiated populations by geographic origin. Finnish samples (n=93) were 
among the most differentiated samples showing excess of low-frequency variants reflecting 
an increase in the population size after a recent bottleneck (1000 Genomes Project 
Consortium et al., 2012). Most importantly, the analysis tools and data generated by the 1000 
Genomes Project facilitate NGS sequencing studies of human diseases. 
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2.2 Genetics of human disease 
2.2.1 Disease-causing genetic changes 
DNA variations in the gene coding regions of the genome may alter the function of the 
encoded proteins and potentially lead to a disease phenotype. SNVs causing a premature stop 
codon (nonsense mutation) and indels causing a change in the reading frame of a gene 
(frameshift mutation) are considered truncating changes, which most likely yield a non-
functional protein product. Furthermore, nucleotide changes in the vicinity of splice junctions 
are often harmful due to splicing defects. Nonsense, frameshift and splice-site mutations are 
enriched among disease-causing variants, although non-synonymous missense changes may 
also be damaging for the protein function (Cooper and Shendure, 2011).  
Delineation of disease-causing variants can be achieved by approaches such as family-based 
linkage analysis followed by sequencing of candidate regions and genetic validation in 
patients with a similar phenotype (Cooper and Shendure, 2011). Often the genetic information 
is insufficient to conclude causality because of low number of family and patient samples 
available for the study. In many cases, experimental and computational approaches can be 
used to assess variant function. Prediction of pathogenicity of variants, especially in the case 
of missense changes, relies on sequence conservation in many species, on biochemical 
properties of amino acids and on structural information of the encoded protein. An example of 
this kind of prediction tool is PolyPhen-2 (Adzhubei et al., 2010). Recent NGS studies have 
shown individual genomes to harbor on average 150-179 loss-of-function variants (nonsense, 
frameshift and splice-site variants) (1000 Genomes Project Consortium et al., 2012; Shen et 
al., 2013). However, the numbers of rare (<0.5%) variants were much less, such that 
individuals are estimated to carry up to 20 rare loss-of-function and disease associated 
variants (1000 Genomes Project Consortium et al., 2012). Therefore variant frequencies in the 
population are important to take into consideration when assessing candidate pathogenic 
variants (MacArthur et al., 2014). 
Chromosomal changes which delete, duplicate or rearrange genetic material have originally 
been detected by cytogenetics and used for positional cloning of single-gene disorders 
(Tommerup, 1993; Vissers et al., 2005). Many disease phenotypes caused by a deletion are 
due to haploinsufficiency of dosage-sensitive genes, meaning that a single copy is not enough 
for the gene to function properly. Deletions that span one or more exons are estimated to 
account for up to 15% of all mutations in monogenic diseases (Vissers et al., 2005). However, 
often the deletions and duplications found in single patients are novel or extremely rare, and 
occurrence in multiple patients is required for disease gene stratification and clinical 
interpretation. Centralized databases such as DECIPHER (Database of Chromosomal 
Imbalance and Phenotype in Humans Using Ensembl Resources) have been established to 
enable data sharing especially in rare disease studies (Firth et al., 2009). 
Cancer is thought to arise from mutations that accumulate in descendants of a cell over time. 
Cancer development is an evolutionary process of acquisition of somatic variation in 
individual cells and selection of cells with growth advantage. A combination of advantageous 
mutations allows a cell to proliferate autonomously and drives a clonal expansion (Stratton et 
al., 2009). The idea known as the two-hit hypothesis was first proposed by Knudson (1971): 
tumors develop when inactivating mutational events occur in both copies of a gene that has a 
growth-suppressive function in normal cells (a tumor suppressor gene). In particular, if the 
first recessive mutation is inherited in germline and the second mutation is acquired 
somatically, cancer occurs at a younger age than if both mutations are somatic (Knudson, 
1971). In hereditary cancers, the wild type allele of a tumor suppressor gene is frequently lost 
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in tumors through a large-scale somatic deletion or mitotic recombination, both of which can 
be detected as regions of loss-of-heterozygosity (LOH) (Hansen and Cavenee, 1987). 
Recurrent somatic amplifications, translocations or deletions distributed along particular 
genes across tumors might indicate that alterations at these sites constitute tumor progression. 
Tumor suppressors can most easily be identified at genomic sites displaying homozygous 
deletions in tumors, whereas amplifications likely contain oncogenes, defined as genes whose 
protein product is abnormally activated increasing cell survival and proliferation (Hanahan 
and Weinberg, 2011; Vogelstein et al., 2013). 
Studies have shown that somatic point mutations are the most prevalent type of changes 
affecting protein coding genes, although the rate of chromosomal changes is elevated in 
tumors (Hanahan and Weinberg, 2011; Vogelstein et al., 2013). Gains and losses of copy 
numbers in tumor cells are induced by genomic instability during tumor progression 
(Hanahan and Weinberg, 2011). NGS technologies have revealed that some copy number 
changes seen in cancer and developmental disorders can arise from complex chromosomal 
rearrangements involving at least three genomic breakpoints (Zhang et al., 2009). Recently, a 
phenomenon termed chromothripsis was described with tens to hundreds of clustered 
rearrangements accompanied with focal losses which had occurred simultaneously in a single 
event (Figure 1). The massive remodeling event was suggested to affect one or few 
chromosomes and at least 2-3% of all cancers (Stephens et al., 2011). Since its discovery, 
chromothripsis has also been shown to inactivate genes that drive tumorigenesis, such as RB1 
in retinoblastoma, or to create oncogenic fusions (McEvoy et al., 2014; Parker et al., 2014). 
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Figure 1. An example of chromothripsis in a chronic lymphatic leukemia patient sample.  
(A) Clustered complex rearrangements generate copy number oscillation between 1 and 2 at genomic 
locations 70-170 Mb on chromosome 4. (B) Nine interchromosomal rearrangements join the 
chromosome 4q to chromosomes 1, 12 and 15. Chromosomes are organized circularly in the outer ring. 
Somatic rearrangements are shown as the colored links between the two relevant genomic locations. 
Modified from Stephens et al. (2011), copyright 2011 Elsevier Inc. Reuse permitted by Creative 
Commons public licence. 
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Many published studies have focused on disease-causing changes in the coding regions of the 
human genome as functional interpretation of their consequences is more evident. Genetic 
changes in noncoding regulatory regions of genes may disrupt transcription factor binding and 
increase or decrease transcriptional activity of genes. Annotations such as guanine-cytosine 
content, evolutionary conservation, DNase I hypersensitivity, histone modifications and 
distance to the nearest transcription start site (TSS) are the best indicators of functionality of 
noncoding regions. HGMD (the April 2012 release) contains 1,614 germline variations 
annotated as 'regulatory mutations' of which 75 % are located within a 2 kb distance to an 
annotated TSS (Ritchie et al., 2014).  
Genome-wide association studies (GWAS), population-based case-control studies testing for 
association between SNPs and a trait in hundreds or thousands of persons, have identified a 
large number of genetic loci for common diseases (Manolio, 2010). The associated SNP may 
be causative itself or genetically linked with another variation that is disease-causing. 
Majority of variants identified in the published GWAS studies till December 2008 were 
common (MAF>5%), associated with modest effect sizes (median odds ratio 1.33), and 
located in intronic (45%) or intergenic (43%) regions suggesting that noncoding variants have 
a role in the etiology of common diseases (Hindorff et al., 2009). 
Genetic changes which have been associated with diseases and published in the peer-reviewed 
literature are collected into central repositories. HGMD collects germline mutations that 
underlie or have an association with inherited diseases (Stenson et al., 2013), whereas 
COSMIC gathers information on somatic mutations in cancer (Forbes et al., 2011). Continual 
reassessment of the data is needed since NGS datasets in apparently healthy individuals, such 
as the 1000 Genomes project data, are bringing into question the pathogenicity of previously 
reported disease-causing mutations. In a recent high-throughput sequencing study of 104 
unrelated individuals, 27% (122/460) of published severe recessive disease-causing mutations 
were found to be common polymorphisms, sequencing errors or lacking evidence for 
pathogenicity (Bell et al., 2011). However, disease-causing variants with reduced penetrance 
are not uncommon, and there are many examples of modifier variants, for example, that 
influence penetrance of diseases (Cooper et al., 2013). 
2.2.2 Genetic epidemiology 
Combination of two disciplines, genetics and epidemiology, has been considered as a distinct 
entity, genetic epidemiology since mid-1980s. Genetic epidemiology “focuses on the role of 
genetic factors and their interaction with environmental factors in the occurrence of disease in 
human populations”, although different views on the scope of genetic epidemiology exist 
(Khoury et al., 1993). Some of the definitions restrict genetic epidemiology mainly to the 
study of familial aggregation, whereas other definitions emphasize the joint analysis of 
genetic and environmental factors in disease etiology. The broad goal of genetic 
epidemiology is to understand genetic background of diseases at population level, and to work 
towards disease control and prevention (Khoury et al., 1993). 
Research strategies of genetic epidemiology comprise of population and familial aggregations 
studies. Population studies try to determine the distribution of diseases and genetic traits in a 
population and the role of genetic factors in disease etiology (Khoury et al., 1993). According 
to King et al. (1984), studies of familial aggregation address three main questions: does a 
disease cluster in families; is familial clustering caused by common environmental exposure, 
inherited susceptibility or culturally transmitted risk factors; and, finally, what is the model of 
inheritance. Genealogical data in the Utah Population Database, Swedish Family-Cancer 
Database and Icelandic Cancer Registry have been employed in the largest familial 
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aggregation studies of cancer (Albright F Ph et al., 2012; Amundadottir et al., 2004; Czene et 
al., 2002; Goldgar et al., 1994). 
Epidemiological measures of relative risk are used to examine association between exposure 
and disease occurrence. For example, relative risk for familial aggregation can be calculated 
by comparing disease frequency in relatives of affected individuals with disease frequency in 
relatives of unaffected individuals or with general population (Khoury et al., 1993). Three 
types of measures of relative risk, namely risk ratio, rate ratio and odds ratio, can be 
calculated. In particular, a relative risk value greater than 1.0 indicates an increased risk for 
the disease among individuals in the exposed group. If no direct data is available for the 
comparison group, proportional incidence measures can be calculated by dividing observed 
number of cases (O) by the expected number (E). Population sub-groups (strata) may have 
marked differences in disease occurrence, which is adjusted by calculating stratum-specific 
measures (Santos, 1999). 
In addition to familial aggregation studies, contribution of genetic and environmental factors 
in disease etiology can be estimated with twin studies (King et al., 1984). As twins share 
many environmental exposures and cultural risk factors, monozygotic (MZ) and dizygotic 
(DZ) twins should be 100% and 50% concordant for the disease, respectively, if the disease 
was completely genetically determined. A twin study based on data from Swedish, Danish 
and Finnish twin registries found concordances less than 10% for many of the cancer sites 
examined (Lichtenstein et al., 2000). Most of the concordances were greater in MZ than in 
DZ twins, supporting the existence of a genetic factor. Heritability was estimated using a 
statistical model in which phenotypic variance in twins was divided into hereditary, shared 
environment and non-shared environment components. The highest hereditary effects (26%- 
42%) were observed for stomach, colon/rectum, breast, prostate and lung cancers. The risk of 
getting stomach cancer, for example, was estimated to be accounted for by 28% of hereditary, 
10% of shared environment and 62% of non-shared environment effects (Lichtenstein et al., 
2000).  
The difficulty in multifactorial models of inheritance is to specify the effects of various non-
genetic risk factors, which are selected based on tractability rather than understanding of 
underlying biological mechanism in disease etiology. Unfortunately, increase in genomic 
information has not yet been followed by development of methodologies to study joint effects 
of genes and environment (Khoury et al., 2011). 
2.2.2.1 Isolated populations 
Families with multiple affected individuals are important in finding evidence for genetic 
factors in diseases. Affected individuals derived from heterogeneous populations may provide 
limited power for association and linkage studies because the phenotype of individuals with 
genetic predisposition can vary under different environmental conditions, and there can be 
different genetic causes. Therefore homogeneous populations, especially isolated populations 
are often utilized in the mapping of disease genes (Heutink and Oostra, 2002).  
The relatively homogenous Finnish population, encompassing around 5.4 million people, has 
been successfully utilized in the gene mapping of Mendelian disorders. The Finnish 
population has traditionally been divided into early-settlement and late-settlement regions. 
The southwest and southeast coastal regions, recognized as the early settlement, were 
inhabited first in the history of the Finnish population. In the sixteenth century, the population 
in the small southeastern area started to expand to the inland areas of Finland resulting in the 
late settlement (Peltonen et al., 1999b). Ten distinct subpopulations have been identified 
17 
 
among early- and late-settlement regions with high-density SNP genotyping, suggesting 
multiple bottlenecks and population growth by expansion in these wide inland areas of 
Finland. The youngest subisolates in the north-east of Finland were shown to display higher 
homozygosity across the genome as compared to the early-settlement population, and high 
linkage disequilibrium as compared to other isolates worldwide (Jakkula et al., 2008). The 
small number of founders in isolated populations allows enrichment of diseases caused by 
single-origin mutations, which can be studied in consanguineous patients. In Finland, the 
information on relatedness of patients can be derived from genealogical records in the parish 
registries and in the National Population Registry (NPR) since 1580 (Peltonen et al., 1999a). 
2.2.3 Phenotypes relevant in this thesis 
In this thesis, both monogenic and complex diseases were studied by means of genetics and 
epidemiology. Monogenic diseases with full penetrance are assumed to obey the dominant or 
recessive Mendelian patterns of inheritance, while factors such as incomplete penetrance, age 
at onset and phenocopies complicate identification of disease segregation. Monogenic 
diseases might also arise in a patient due to a new, de novo mutation. Complex diseases are 
multifactorial diseases that arise from combination of genetic, environmental and life-style 
factors. Monogenic inheritance might also be oversimplified in many Mendelian traits 
because of combinatorial effects of multiple genetic factors on a single patient’s phenotype 
(Badano and Katsanis, 2002). Diseases that follow simple Mendelian patterns of inheritance 
tend to be rare, whereas many common diseases, such as cancer, are complex. 
Sporadic cancers can often have the same underlying genetic defects that have been identified 
in Mendelian cancer predisposition families. Cancer predisposition is a rare condition that is 
estimated to account for approximately 3% of cancers, although 40% of the cancer 
predisposition genes are found to be mutated also in sporadic tumors (Rahman, 2014). For 
example, high-penetrance germline mutations in genes such as MLH1, MSH2, APC and MYH 
have been identified in large cancer syndrome families (MIM #609310, #120435, #175100, 
and #608456, respectively), and the predisposed individuals account only for up to 5% of all 
colorectal cancer (CRC) cases (Aaltonen et al., 2007). However, the same genes and signaling 
pathways are also central in the development of sporadic colorectal tumors. 
2.2.3.1 Heterotaxy syndrome and isomerism (I) 
During the development of the vertebrate embryo, there is an initial event breaking the 
bilateral symmetry and a consequent establishment of left-right information with side-specific 
gene expression. Studies on various vertebrate model organisms have revealed similarities as 
well as divergences in left-right axis determination pathways that seem to converge on a node, 
which is a transient structure formed during the cell-migrating phase of a developing embryo 
(gastrulation) (Raya and Belmonte, 2006). Cells in the node are monociliated and the 
clockwise rotation of the cilia generates a leftward flow of extracellular fluid known as nodal 
flow, which is suggested to initiate the left-right asymmetry (Nonaka et al., 1998; Okada et al., 
1999). 
Defects in the left-right axis specification during embryogenesis result in abnormal 
arrangement of asymmetrical structures in the human body. The normal arrangement is 
designated as situs solitus, while the two types of abnormal arrangement are situs inversus, a 
complete and mirror-imaged reversal of asymmetrical organs, and situs ambiguus, a 
combination of situs solitus and situs inversus. Situs ambiguus is also called as heterotaxy 
syndrome, isomerism sequence, and Ivemark, asplenia or polyasplenia syndrome. Heterotaxy 
syndrome is considered whenever asymmetrical organs are not in their usual or mirror-imaged 
arrangement (Cohen et al., 2007).  
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Heterotaxy syndrome is subdivided into right atrial isomerism (RAI) and left atrial isomerism 
(LAI), whose characterization can be based on atrial appendages that have right-sided or left-
sided morphology on both sides of the heart, respectively (Cohen et al., 2007). In addition to 
complex cardiac malformations, right isomerism is often associated with asplenia, whereas 
left isomerism is associated with polysplenia (Ivemark, 1955). In addition, the lungs can be 
bilaterally trilobular or bilobular, and stomach and liver can be located in abnormal positions 
in the abdomen (Cohen et al., 2007). Patients with RAI or LAI may have different 
combinations of cardiac and extra-cardiac anomalities, although cardiac anomalities mainly 
dictate the long-term outcome of the patients. RAI is considered to have worse prognosis as 
compared to LAI because of more severe cardiac defects (Lim et al., 2005). 
Familial heterotaxy has been reported with autosomal dominant, recessive and X-linked 
inheritance. Affected siblings within a heterotaxy family may have different situs variants, 
which illustrates the heterogeneity of laterality defects and the complexity of left-right axis 
development (Casey, 1998). Mutations in the ZIC3 gene are reported to cause heterotaxy in 
multiple families showing X-linked inheritance (MIM #306955). In a study by Gebbia et al. 
(1997), affected males with mutations in ZIC3 had situs ambiguus, whereas heterozygous 
females in four of the families were anatomically normal. In one family, three out of nine 
heterozygous females had situs inversus, but the rest of the heterozygous females were 
unaffected (Gebbia et al., 1997). 
Primary ciliary dyskinesia (PCD) is a laterality defect that arises as a result of structurally and 
functionally defective cilia. PCD patients have often respiratory and upper airway symptoms, 
male infertility, and situs inversus (Noone et al., 2004). A small portion of PCD patients have 
heterotaxy, and cardiac and/or vascular abnormalities which are associated with mutations in 
the genes that code for outer dynein arm components of cilia, such as DNAI1 and DNAH5 
(Kennedy et al., 2007). Variations in the CFC1 (MIM #605376), ACVR2B (MIM #613751), 
NODAL (MIM #270100), CCDC11 (MIM #614779) and LEFTY2 genes, as well as a 
translocation breakpoint at 6q21 have been reported in patients with autosomal heterotaxy or 
left-right axis malformations (Bamford et al., 2000; Kato et al., 1996; Kosaki et al., 1999a; 
Kosaki et al., 1999b; Mohapatra et al., 2009; Peeters et al., 2001; Perles et al., 2012). Of these, 
only CCDC11 has been associated with autosomal recessive inheritance of heterotaxy. 
2.2.3.2 Intellectual disability (II) 
Intellectual disability (ID), also known as mental retardation or early-onset cognitive 
impairment, refers to a condition with delayed development and reduced ability to cope 
independently. Severity of retardation can be assessed in early childhood with tests measuring 
verbal and motor performance. Diagnosis of ID is based on an intelligence quotient (IQ), and 
individuals with IQ<50 are considered to have a severe form of ID (Ropers, 2010). 
Conventionally, the disease is further categorized as syndromic ID, if other abnormalities 
exist beside cognitive impairment. 
ID has several environmental risk factors, including malnutrition, maternal transmission of 
infectious diseases and fetal alcohol exposure. In developed countries, severe form of ID is 
mostly genetically determined. Chromosomal changes are estimated to account for ~25% of 
all patients with ID, and X-linked gene defects for ~10% of males with ID. Down syndrome 
(#190685) caused by trisomy of chromosome 21 is the most frequent genetic form of ID. 
Cytogenetically visible deletions have been identified in a number of ID syndromes with 
recognizable clinical features, such as Prader-Willi syndrome (MIM #176270) and Angelman 
syndrome (MIM #105830) (Ropers, 2010). Both of these syndromes have multiple genetic 
and epigenetic etiologies but the majority of the cases (~70%) have de novo interstitial 
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deletion of 15q11-q13 (Horsthemke and Wagstaff, 2008). The FMR1 gene defect on X 
chromosome, which underlies the fragile X syndrome, is the second most frequent genetic 
cause of ID (MIM #300624) (Rousseau et al., 1995). Many inborn errors of metabolism, such 
as phenylketonuria (MIM #261600), are recessively inherited ID disorders with mutations in 
individual genes that code for enzymes (Ropers, 2010). Genetic causes of X-linked ID are 
known better than those of autosomal recessive ID, although autosomal recessive ID is 
considered to be the most common form of ID in populations with high rate of parental 
consanguinity (Musante and Ropers, 2014). Recently, NGS technologies have revealed novel 
genes for autosomal dominant de novo ID and autosomal recessive ID (de Ligt et al., 2012; 
Najmabadi et al., 2011). The large number of known ID genes demonstrates that the etiology 
of ID is genetically heterogeneous. 
2.2.3.3 Uterine leiomyomas (III) 
Uterine leiomyomas (also known as fibroids) are benign smooth muscle tumors with an 
estimated prevalence of 70-80% among women of reproductive age (Catherino et al., 2011; 
Cramer and Patel, 1990). Leiomyomas can cause a variety of symptoms, including abdominal 
pain and excessive uterine bleeding, determined by the size and location of the tumor. Severe 
symptoms develop in 15-30% of women (Catherino et al., 2011). One large predominant 
tumor or many tumors of varying size can grow in a single uterus. The ovarian hormones 
estrogen and progesterone are essential for leiomyoma growth (Bulun, 2013). Uterine 
leiomyomas rarely develop into malignant cancer, and they are the most common medical 
reason for hysterectomy (Cramer and Patel, 1990; Leibsohn et al., 1990). 
Epidemiological studies have suggested African-American ethnicity, obesity, age and 
nulliparity to increase the individual risk for leiomyomas (Flake et al., 2003). Many of the 
risk factors have been proposed to have an effect on estrogen and progesterone levels, which 
in turn increase the likelihood of somatic mutations and tumor formation (Rein, 2000). 
Existence of inherited genetic predisposition has been suggested based on higher incidence of 
leiomyomas among African-American women (Marshall et al., 1997) and higher concordance 
for leiomyomas in MZ than in DZ twin pairs (Luoto et al., 2000).  
Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome (MIM #150800) was 
identified in several families with multiple cutaneous and uterine leiomyomas, and the 
predisposition locus was localized to chromosome 1q42.3-q43 (Alam et al., 2001; Launonen 
et al., 2001). Subsequently, heterozygous germline mutations were identified in the fumarate 
hydratase (FH) gene (Tomlinson et al., 2002). FH has been shown to be a classical tumor 
suppressor gene inactivated by loss of the wild type allele in patients’ tumors (Alam et al., 
2001; Kiuru et al., 2001; Launonen et al., 2001). Somatic bi-allelic inactivation of FH has 
also been reported in a small subset (1.3%) of nonsyndromic leiomyomas (Lehtonen et al., 
2004). 
The most common cytogenetic changes detected in leiomyomas involve translocations 
between chromosomes 12 and 14 [t(12;14) (q14-q15;q23-q24)], deletions on chromosome 7 
[del(7)(q22q32)] and abnormalities at 6p21 (Flake et al., 2003). These rearrangements target 
the high mobility group AT-hook genes, HMGA2 at 12q14-15 and HMGA1 at 6p21 (Ligon 
and Morton, 2000), and RAD51 paralog B (RAD51B) at 14q24 (Ingraham et al., 1999). These 
nonrandom chromosomal changes are detected in approximately 40-50% of leiomyomas 
(Flake et al., 2003). However, the most frequent somatic mutations are observed in the 
mediator complex subunit 12 (MED12) gene affected mainly by point mutations and, to a 
lesser extent, with indels and splice site defects. MED12 mutations are found in 70% of 
leiomyomas, regardless of ethnic background of patients (Mäkinen et al., 2011a; Mäkinen et 
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al., 2011b). The mutations in MED12 are specific to exon 2 and have not been detected to co-
occur with HMGA2 alterations (Mäkinen et al., 2011b; Markowski et al., 2012). 
2.2.3.4 Kaposi sarcoma (IV) 
As first described by Moritz Kaposi (1872), Kaposi sarcoma (KS) appears as brownish red to 
bluish red skin lesions, although tumors can also develop in other organs, such as oral cavity, 
lymph nodes and gastrointestinal tract. At the start of the AIDS epidemic, KS was found to be 
enriched among homosexual men with human immunodeficiency virus (HIV) infection (Safai 
et al., 1985), suggesting an infectious etiology.  Human herpesvirus 8 (HHV8), also known as 
Kaposi sarcoma herpesvirus, was identified as the cause for the disease in 1994 (Chang et al., 
1994). HHV8 is primarily transmitted through saliva, and it can establish life-long latency in 
blood cells of a human host after initial infection. Lytic reactivation causes release and 
dissemination of progeny viruses that can subsequently infect dermal cells and cause disease 
manifestation in the host. Reduced immunity is essential for HHV8 reactivation (IARC 
Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012). 
KS is one of the most important viral-induced cancers, although its incidence varies strongly 
in different populations. KS has the highest incidence in sub-Saharan Africa, mostly due to 
the spread of HIV and high seroprevalence rate (>40%) of HHV8 (Mesri et al., 2010). In 
addition to HIV infected individuals, immunosuppressed patients after organ transplantation 
are at higher risk for KS (Mbulaiteye and Engels, 2006). HHV8 infection alone is not 
sufficient for KS development, and genetic predisposition to KS has been reported in few 
isolated childhood cases with recessive loss-of-function mutations in IFNGR1, WAS, STIM1 
and TNFRSF4 (Byun et al., 2010; Byun et al., 2013; Camcioglu et al., 2004; Picard et al., 
2006). 
2.3 Genome-wide methods for studying genetic diseases 
2.3.1 DNA microarrays 
Microarray based whole-genome SNP genotyping is commonly used in genetic mapping of 
diseases. Illumina’s (Illumina Inc., San Diego, CA, USA) genotyping process with Infinium 
assay consists of four steps: (i) whole-genome amplification, (ii) hybridization to an 
oligonucleotide probe array, (iii) array-based primer extension SNP scoring, and (iv) signal 
amplification/staining (Gunderson et al., 2005). Amplified genomic DNA is hybridized to an 
array that contains synthetic oligonucleotide probes of 75 bases, of which 50 bases are for 
target capturing and 25 bases for decoding. Illumina’s BeadChip arrays are manufactured 
using oligonucleotide probes immobilized on microscopic beads, which are self-assembled 
into wells on arrays. After random assembly of beads into wells, decoding is performed to 
identify the location of each bead type (Steemers and Gunderson, 2005). In a single-base 
extension assay, one bead type is designed to capture each SNP locus. The probe sequences 
are designed to capture genomic DNA so that the 3’ terminal base of a probe sequence is the 
base before a SNP locus, and the primer extension with either of the two hapten-labelled 
dideoxynucleotides (one for C and G, and one for A and T) corresponds to the complementary 
base on the genomic sequence. Probes with hapten-labelled nucleotides at the 3’ end are 
labelled with either Cy3 or Cy5 fluorescent dye, and the signal is amplified with 
immunohistochemistry-based methods for the image scanning of the array (Steemers et al., 
2006). Infinium assay generates two intensity values (X, Y) for each SNP; one for each 
fluorescent dye corresponding to the two alleles (A, B) of the SNP. Illumina’s BeadStudio, 
and more recently GenomeStudio, analysis software (Illumina Inc.) read and normalize the 
intensity data. The normalization algorithm adjusts the dye-dependent background and scales 
the intensity values to ~1 on a sub-bead pool level that is a set of beads manufactured together 
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(Peiffer et al., 2006). This normalization process is needed to generate accurate genotyping 
calls for downstream analyses. 
Gene expression profiling using microarrays allows quantitative analysis of tens of thousands 
of ribonucleic acid (RNA) molecules simultaneously (Lockhart et al., 1996). For example, the 
Affymetrix GeneChip Human Exon Array (Affymetrix, Santa Clara, CA, USA) contains 
oligonucleotide probes which are complementary for exonic sequencies over 25 bp in length 
for a variety of annotated human, mouse or rat complementary DNAs (cDNAs). With this 
probe selection, transcript diversity, such as novel splice-variants, can be detected. Labeled 
RNA samples are hybridized on arrays that contain synthesized probes in known locations, 
and signal intensities of the hybridization reactions are measured (Lockhart et al., 1996). 
Typically each molecule of interest is represented by a probeset that contains 11-20 probes. 
Technical noise and probe-specific affinities affect signal intensities, which need to be 
normalized across arrays before comparison of expression levels. Robust multi-array average 
(RMA) method (i) corrects for background signal, (ii) uses quantile normalization, and (iii) 
performs the median polish procedure to the log2 transformed normalized probe intensities, 
selected to contain only perfect match probes (Irizarry et al., 2003). Median polish proceduce 
is used to protect against outliers by smoothening probe signal intensities between arrays of 
the same experiment and probes of the same probeset. The method operates on matrices 
where rows represent different arrays of an experiment and columns represent probes of a 
probeset. Median values of rows and columns are repeatedly substracted from probe intensity 
values in a matrix until the matrix stabilizes or a limit on the number of iterations is reached 
(Holder et al., 2001). The final values in a matrix after iterations are substracted from the 
original probe intensity signals. The average over probe signal intensities of a probeset is then 
used as a measure of the expression of a molecule of interest. As the information on the 
human genome and transriptome has evolved since the design of the GeneChip arrays, 
reassignment of probes into probesets representing known genes, transcripts and exons can be 
done with customized chip description files (CDF files) during signal processing (Dai et al., 
2005). 
2.3.2 Genetic linkage analysis 
Sequential alleles which are inherited together in a chromosome from a parent to an offspring 
are genetically linked. Alleles in the same parental haplotype are separated only through 
meiotic recombination, in which paired chromosomes exchange homologous DNA sequences. 
The frequency of these recombination events between chromosomal loci is not equivalent to 
their physical distance in basepairs which is why another distance metric, centimorgan (cM), 
is used to describe genetic linkage. One centimorgan is equal to 1% change of a 
recombination event between two loci in a chromosome. An early linkage map of human 
chromosomes was created in the 1980s using restriction fragment length polymorphisms to 
represent the order of loci in centimorgans (Botstein et al., 1980). Nowadays, SNPs are 
commonly used as markers in linkage maps. 
Genotypes of polymorphic markers whose map positions are known are used in family-based 
linkage analysis to test for co-inheritance with the disease. Depending on an assumed disease 
inheritance model, affected members of a family should have the same combination of alleles 
in both chromosomes (recessive inheritance) or in one chromosome (dominant or X-linked 
inheritance) within the genomic region causing the disease (trait locus).  
To calculate statistics for linkage between two loci, Morton (Morton, 1955) introduced the 
logarithm of odds (LOD) score method. The probability of meiotic recombination between 
two loci is called the recombination fraction, theta (θ). The recombination fraction never 
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exceeds the value 0.5, which represents a situation where two loci are segregating 
independently, in other words, they are located on separate chromosomes or far apart from 
each other in the same chromosome. The LOD score method compares, if the likelihood L(θ), 
where θ is any recombination fraction between 0 and 0.5, for two loci is higher than the null 
hypothesis, L(θ=0.5) for no linkage. The LOD score is the logarithm of the likelihood ratio: 
Z(θ) = log10[L(θ) / L(θ=0.5)].  
In order to calculate the likelihood L(θ), the numbers of recombinant (r) and nonrecombinant 
(s) family members are determined. The LOD score equation then is 
Z(θ) = log10 [(1 - θ)
s
 θr / (0.5)r+s]. 
The haplotypes of parental chromosomes should be known once the numbers of recombinant 
and nonrecombinant cases are calculated. However, there might be several equally likely 
phases of parental chromosomes, so the overall likelihood L(θ) becomes a sum of likelihoods. 
For example, if there are two equally likely parental phases, the LOD score equation is: 
Z(θ) = log10 {[½ (1 - θ)
s1
 θr1+ ½ (1 - θ)s2 θr2] / [½ (0.5)r1+s1+½ (0.5)r2+s2]} 
The value of LOD score is determined at a recombination fraction θ that maximizes the log-
likelihood. The LOD score >3 is traditionally used as a criterion for linkage in autosomes 
(Morton, 1955). This represents the likelihood ratio of 1000:1, but in small pedigrees where 
the number of family members is limited, the threshold cannot usually be reached. 
Linkage analysis for more than two loci is performed with multipoint linkage methods which 
have more power to detect linked chromosomal regions. First, the inheritance pattern of 
marker genotypes at each locus is determined for a pedigree. Second, the likelihood ratio for 
the inheritance pattern is calculated under the hypothesis that the locus is a trait locus versus 
the hypothesis that a disease is unlinked to the locus (Kruglyak et al., 1996). In parametric 
linkage analysis, the scoring depends on the assumed penetrance values and allele frequencies 
for the tested locus. 
Multipoint linkage analysis is a computationally intensive task, and different approaches exist. 
These include the Elston-Stewart algorithm (Elston and Stewart, 1971), Lander-Green 
algorithm (Lander and Green, 1987) and Markov-Chain Monte-Carlo method (Guo and 
Thompson, 1992), which serve as a basis for more sophisticated linkage analysis programs. 
The Lander-Green and Markov-Chain Monte-Carlo approaches are implemented in MERLIN 
(Abecasis et al., 2002) and SimWalk2 (Sobel and Lange, 1996), respectively. These were the 
linkage analysis programs used in this thesis. 
2.3.3 Next-generation sequencing technologies 
The most widely used NGS technology, which is well suited for variant discovery in human 
genome resequencing studies, was developed by Illumina (Metzker, 2010). The genomic 
DNA is first randomly sheared into fragments of a certain size distribution, adaptors are 
ligated to the ends of target fragments, and polymerase chain reaction (PCR) amplification is 
performed. These target libraries are immobilized onto a glass slide (flowcell), where each 
DNA molecule is clonally amplified to form millions of spatially separate clusters that 
undergo the sequencing reaction. Sequencing is performed in repeated cycles of single-base 
extension by adding all four nucleotides labeled with different dye and using four-color 
imaging. Each nucleotide signal is a consensus of the identical templates in the clusters, and a 
measure of uncertainty (a quality value) for each base is applied by a base-calling algorithm. 
In the paired-end setting, opposite strands from both ends of DNA fragments are sequenced 
23 
 
(Bentley et al., 2008). Typically, millions of DNA fragments of about 300-400 bp on average 
are sequenced in parallel with 100 bp read length from both ends in the whole-genome 
sequencing (WGS) applications of the Illumina technology. 
In addition to WGS, the Illumina NGS technology can be used to study whole-transcriptome 
(RNA sequencing), or targeted genomic regions, such as protein coding regions (exome 
sequencing) or DNA binding sites of proteins (ChIP-sequencing) (Metzker, 2010). 
Another NGS technology, developed by Complete Genomics (CG) (Complete Genomics Inc., 
Mountain View, CA, USA) uses DNA nanoballs to obtain tandem copies of fragmented 
genomic DNA. Each DNA nanoball contains adapters inserted in a fragmented DNA 
molecule which is circularized. Sequencing is performed by adding fluorescent-labeled 
probes that are anchored by the adapter sequences (Drmanac et al., 2010). This combinatorial 
probe-anchor ligation technology avoids accumulation of errors in contrast to sequencing by 
synthesis reaction used in the Illumina technology. CG sequencing is available only as a 
service that includes all sequencing data processing, and customers are provided with 
annotated variant calls. 
2.3.4 Next-generation sequencing data analysis 
2.3.4.1 Read alignment 
Human genome resequencing studies start with the alignment of raw sequencing reads to the 
known reference genome. Aligners such as ELAND and Burrows-Wheeler Alignment tool 
(BWA) allow the mapping of a large volume of short (~35-100 bp) sequencing reads 
produced with the Illumina NGS technology (Bentley et al., 2008; Li and Durbin, 2009). The 
reference genome is scanned to find best matches for each read utilizing string matching 
algorithms, and allowing a specified number of mismatches and indels as compared to the 
reference sequence. The memory and time requirements for scanning millions of reads 
through the whole reference sequence are manageable using Burrows-Wheeler transform as 
implemented in BWA. The per-base quality values are utilized to weight the contribution of 
each base call to the alignment of a sequencing read. When processing paired-end data, the 
two reads from the opposite ends of a sequenced fragment can be aligned together to find the 
most likely mapping position in the reference genome (Li and Durbin, 2009). A measure of 
confidence, mapping quality, is reported for each read alignment by aligners, and alignments 
are output in the standard SAM (Sequence Alignment/Map) or BAM (Binary Alignment/Map) 
format (Li et al., 2008; Li and Durbin, 2009). 
About 50 % of the human genome comprises of repetitive DNA sequences. These regions 
cause most of the problems in the alignment of short sequencing reads. If a read is shorter 
than a repetitive DNA sequence, it can map equally well to multiple locations in the genome. 
Sometimes a uniquely mapping read-pair can aid the alignment to the correct position. 
Aligners have different strategies to handle reads that map to multiple locations but correct 
interpretation of variant calls within repetitive regions remains challenging without increasing 
the length of sequencing reads (Treangen and Salzberg, 2011). 
Reads spanning indels are also difficult to align with the fast string matching algorithms. 
Mapping of these reads may result in misalignments where many bases of the spanning reads 
show mismatches, and may be falsely considered as SNVs in the variant calling. Therefore 
initial alignments can be refined using local realignment of the reads around predicted indel 
positions utilizing multiple sequence alignment methods. In a well-characterized sample of 
the 1000 Genomes Project, 15% of reads spanning known indel sites were initially misaligned. 
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Of these, local realignment was shown to eliminate 1.8 million loci with significant number of 
mismatches (DePristo et al., 2011). 
The PCR amplification step in the construction of Illumina sequencing libraries may cause 
some DNA fragments to be overrepresented and thus, many nonindependent sequencing reads 
to span the same bases in the initial alignment. Variant calling, as described next, expects that 
each read represent a unique fragment of DNA of the original sample. Therefore, paired-end 
reads that have exactly the same coordinates in the alignment are marked as duplicates, and 
only the read in the set with the best mapping quality is used in the variant calling (Day-
Williams and Zeggini, 2011). 
2.3.4.2 Variant calling 
Variant calling from high-throughput resequencing data depends on the proportion of non-
reference alleles in the total number of aligned reads at a particular genomic site. Thus, 
sequencing depth has a major influence on accuracy and sensitivity of variant detection. An 
average read depth of at least 30 throughout the genome is recommended for comprehensive 
detection of heterozygous variants in the Illumina NGS data (Bentley et al., 2008). The type 
of study project and NGS data direct the selection of variant analysis approaches. In 
Mendelian disease studies, for example, higher sensitivity is required with the cost of high 
error rate, whereas in population data, higher specificity is favored. Here, a set of programs 
for detection of different types of variants, including SNVs, indels, SVs and CNAs from 
aligned NGS reads are presented, as they were used in the WGS data analysis of this thesis. 
The current NGS technologies can produce high rates of variant artifacts due to base calling 
and alignment errors, which can be controlled for in variant calling by requiring non-reference 
bases to have high base qualities, to account high percentage of the aligned reads, and to be 
present in reads that are mapped on both plus and minus strands of the genome (Mokry et al., 
2010). A framework for NGS data processing, and for SNV and indel calling is offered by the 
Genome Analysis Toolkit (GATK) which is designed for large-scale sequencing data, such as 
for the 1000 Genomes Project data. The GATK Unified Genotyper is a sensitive variant caller 
using the Bayesian genotype likelihood model that determines a phred-scaled confidence 
score for each variant (McKenna et al., 2010). A commonly used verification measure for 
specificity of SNV calling in germline data is the transition to transversion ratio which is 
around 2.1 for the whole genome (DePristo et al., 2011). When analyzing somatic mutations 
from tumors, different variant calling thresholds are required because tumor heterogeneity and 
purity can affect the proportion of non-reference alleles in the aligned reads. The somatic 
analysis tool VarScan 2 processes data from both tumor and normal sample simultaneously, 
and compares SNV or indel calls pairwise at each position that meets the requirement for a 
user-specified minimum read depth. Significance of allele frequency difference in the tumor 
and normal sample is calculated using Fisher’s Exact test, and statistically significant variants 
present in the tumor and not in the corresponding normal tissue are classified as somatic 
(Koboldt et al., 2012). 
BreakDancer is an algorithm to call SVs including deletions, insertions, inversions, and 
translocations from paired-end NGS reads. BreakDancer detects SVs based on clusters of 
discordantly aligned read-pairs which are separated with a distance differing from expected 
insert size distribution, or which have abnormal mapping orientations, in other words, read-
pairs are not on the opposite strands of the reference genome as expected with the Illumina 
NGS technology (Figure 2) (Chen et al., 2009). BreakDancer can detect large SVs with 
similar or higher sensitivity than other methods that utilize discordant read-pairs in variant 
calling (Chen et al., 2009; Pabinger et al., 2014). However, complementary methods are 
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needed to call copy number alterations (CNAs) from the NGS data (Mills et al., 2011; 
Pabinger et al., 2014). Read-depth analysis is commonly used in combination with read-pair 
analysis to detect large CNAs (≥1 kb). VarScan 2, for example, produces normalized and log2 
transformed tumor versus normal depth of coverage ratios along user-specified contiguous 
chromosomal regions, which are further processed with circular binary segmentation to detect 
regions with equal copy numbers (Koboldt et al., 2012; Venkatraman and Olshen, 2007). 
 
Figure 2. Schematic presentation of somatic structural variation (SV) and copy number alteration 
(CNA) calls detected by BreakDancer and circular binary segmentation, respectively, from the paired-
end sequencing reads of a tumor in study III. Upper bar displays the SV and CNA calls on the 
reference chromosome X; lower bar represents the resolved structure of chromosome X of the 
sequenced sample. The two reads from the opposite ends of a sequenced DNA fragment, read1 (R1) 
and read2 (R2) are called discordant, if they are not aligned on the opposite direction (arrows), or if 
the distance between the reads differs from the expected insert size (distribution of distances between 
the 3’ ends of R1 and R2 in the sequenced DNA fragments). Here, BreakDancer detected four clusters 
of discordant read-pairs. SVs 1 and 3 are called as deletions, because reads align to the reference 
genome at longer distance from each other than expected, although the fragments between the 
discordant read-pairs are not truly deleted. SVs 2 and 4 are called as inversions, because reads align in 
the same direction. CNA calls from the read depth analysis revealed two deletions (Del1 and Del2). 
Overall inspection of the calls reveals that the sample has interconnected complex chromosomal 
rearrangements on chromosome X. 
The effects of alignment errors on variant calls can be reduced by multiple sequence 
alignment in regions of likely variation, including SNVs, indels and SVs – a procedure which 
is implemented in CG’s variant calling procedure. SVs in the CG data are first detected based 
on clusters of discordant read-pairs, and high confidence SV calls are then characterized 
whenever local de novo assembly for reads in a breakpoint junction is successful (personal 
communication with Complete Genomics Inc., March 2012). 
Various filtering strategies can be used for variants with low quality or with high frequency in 
a set of controls to further improve specificity of variant calling and delineation of disease-
causing changes. Control data that is produced with the same NGS technology and analyzed 
with the same tools can remove platform and analysis specific sequence artifacts, whereas 
controls selected from the same population are important in removing common 
polymorphisms (MacArthur et al., 2014).  
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3 Aims of the study 
The general aim of this thesis was to develop and apply approaches for efficient analysis of 
large quantities of epidemiological and molecular data. Mastering these approaches allowed 
characterization of genetic causes associated with various human diseases. The specific aims 
of studies I-IV were: 
I To identify genetic basis of right atrial isomerism in a Finnish family using linkage 
analysis combined with a candidate-gene approach 
 
II To elucidate molecular basis of a novel intellectual disability syndrome utilizing 
linkage analysis, homozygosity mapping and whole-genome sequencing 
 
III To analyze whole-genome sequencing and gene expression data to characterize 
genetic alterations in uterine leiomyomas 
 
IV To develop and utilize novel approaches to systematically analyze the Finnish Cancer 
Registry data, and to identify potentially novel cancer susceptibility conditions and 
families 
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4 Materials and methods 
4.1 Study materials 
4.1.1 Isomerism family and samples (I) 
A Finnish family with exceptionally many offspring with RAI had been previously identified 
and reported by Eronen et al. (2004). Five out of seven siblings were affected with RAI, 
asplenia and situs anomalies, and had succumbed to complex heart defects before the age of 
two years. The disease phenotype of the affected children was present already at birth, and the 
abnormal arrangement of abdominal and thoracic organs, including heart, was very similar in 
all cases (see Table 1 in the original publication I). The healthy parents (I-1 and I-2, see 
Figure 1 in the original publication I) were not known to be closely related and no 
occurrences of laterality defects were seen in the family history. The healthy children (II-5 
and II-7) and parents were examined by cardiac and abdominal ultrasound with normal 
findings.  
Genomic DNA was extracted from blood samples of the healthy parents and two healthy 
children, from fibroblast cell lines of three affected children (II-2, II-4 and II-6) and from 
paraffin embedded tissue samples of two affected children (II-1 and II-3). Also blood samples 
from six siblings of the mother and from two sisters of the father were collected and genomic 
DNA extracted. 
DNA samples from 346 anonymous donors of the Finnish Red Cross blood service were used 
as controls in study I. These were selected from the Jyväskylä (n=125), Lappeenranta (n=82), 
Kotka (n=74) and Kuopio (n=65) regions. Also 271 control DNA samples from the UK 
Caucasian blood donors were utilized in the GDF1 mutation screening (Human Random 
Control DNA panels, Sigma-Aldrich, Saint Louis, MO, USA). Additional normal tissue or 
blood samples from 278 CRC patients were chosen for the mutation screening from a sample 
series collected since 1994 at the Jyväskylä Central Hospital. 
4.1.2 Intellectual disability family and samples (II) 
Six patients with an unexplained syndromic form of severe ID developed during infancy (see 
Table 1 in the original publication II) were identified in the same village in the north-east of 
Finland. The patients were born healthy with normal birth weights from uneventful 
pregnancies at normal gestational weeks to healthy parents. Etiological investigations 
including chromosome and copy number analysis and metabolic screening did not reveal the 
cause of ID in the clinic. Fragile-X DNA analysis of three patients and Prader-Willi 
methylation analysis of five patients were also negative. Subsequent genealogical work 
revealed that the patients in the four sibships belong to a large consanguineous family (see 
Figure 1 in the original publication II). One patient had three deceased siblings with ID, but 
no patient records were available and no autopsies were performed. Furthermore, one 
deceased individual (X-1) with severe ID was identified in the extended pedigree, but he did 
not exhibit the same clinical phenotype as characterized in the other six patients. In addition, 
we recruited to the study 15 patients living in the north-east of Finland who were diagnosed 
with severe ID of unknown etiology and had varying degree of compatibility with the patients 
in the study family.  
Individuals and sample materials included in the study are listed in the Supplementary Table 2 
in the original publication II. Blood derived RNA was extracted with Paxgene Blood RNA kit 
(Qiagen, GmbH, Hilden, Germany) and purified with RNeasy MinElute clean up kit (Qiagen). 
Quality and quantity of DNA and RNA samples were measured before WGS library 
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preparation and gene expression array hybridization. cDNA was synthesized from RNA 
samples using random primers (Promega, Madison, WI, USA), M-MLV reverse transcriptase 
enzyme (Promega) and RNAase inhibitor (Promega). 
4.1.3 Leiomyoma samples (III) 
A set of 38 uterine leiomyomas and corresponding normal myometrium tissues were collected 
from 30 patients at hysterectomy at the Helsinki University Central Hospital and snap frozen 
in liquid nitrogen while fresh. Genomic DNA and total RNA were extracted from the tissue 
samples with FastDNA Kit (MP Biomedicals LLC, Solon, OH, USA), and TRIzol Reagent 
(Invitrogen, Carlsbad, CA, USA) or Tri Reagent RT (Molecular Research Center, Inc., 
Cincinnati, OH, USA), respectively. RNA purification was done with RNeasy MinElute clean 
up kit (Qiagen). Quality and quantity of the samples were measured before WGS library 
preparation and gene expression array hybridization. 
4.1.4 Patient data in the Finnish Cancer Registry (IV) 
The Finnish Cancer Registry (FCR) is a nation-wide database collecting data on incident 
cancers and cancer deaths in Finland since 1953. Reporting of new cancer incidences was 
made obligatory for physicians, hospitals, and pathology and hematology laboratories in 1961. 
FCR has high quality data in terms of completeness and accuracy (Pukkala, 2011; Teppo et 
al., 1994).  
In study IV, we considered 1,175,040 neoplasms registered in FCR until 2011, including 
212,685 cases of certain commonly registered precancerous lesions such as basal cell 
carcinoma of skin and polycythemia vera (registered since 1969). Each record of cancer 
incidence was classified according to the International Classification of Diseases (ICD) 
oncology, 3rd edition (ICD-O-3) in the FCR data. We classified tumor types to broader 
topography and morphology groups before systematic clustering, as described in section 4.5.1. 
A total of 878,593 patients had personal identity code (PIC), that is, they had not died before 
1967, and thus their information on family names at birth and municipalities of birth could be 
obtained from NPR. 
4.2 Array-based methods 
4.2.1 SNP array data analysis and genetic mapping (I, II) 
In study I, genome-wide SNP genotyping of six individuals (I-1, I-2, II-2, II-4, II-5 and II-6) 
was performed with Illumina’s HumanCNV370 DNA Analysis BeadChip (Illumina Inc.) at 
the Institute of Molecular Medicine Finland (FIMM) (Helsinki, Finland). Genotype calling 
was carried out with the BeadStudio software (Illumina Inc.) using the default GenCall score 
cutoff (0.15) derived from Illumina’s GenCall application (v 6.3.0). In study II, genome-wide 
SNP genotyping was performed with Illumina’s HumanOmni2.5 chip (Illumina Inc.) from six 
patients’ DNA (XI-3, XI-7, XII-1, XII-4, XII-5 and XII-6) at Estonian Genome Center (Tarto, 
Estonia). Genotype calling was carried out with the GenomeStudio software (Illumina Inc.) 
using the default GenCall score threshold (0.15) and GenCall application (v 6.3.0). 
In study I, a multipoint parametric linkage analysis was performed for autosomes with 
MERLIN (v 1.1.2) (Abecasis et al., 2002) on a CSC server (CSC - IT Center for Science Ltd., 
Finland). The error detection algorithm included in MERLIN was used to flag unlikely 
genotypes from the data. The produced error files and the Merlin linkage files were run with 
pedwipe in MERLIN to erase genotypes flagged as problematic. The parametric linkage 
analysis using the wiped linkage files was performed under a rare recessive disease model: a 
disease allele frequency of 0.0005, and penetrances of 0.0, 0.0 and 1.0 for individuals with 0, 
1 and 2 copies of the disease allele, respectively. Penetrance was set to 1.0 for two disease 
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alleles and 0.0 for other options, since the phenotype of the affected children was seen already 
at birth, and the parents that presumably were carrying one disease allele were confirmed to 
be healthy. No phenocopies were expected. Genetic map (deCode) distances were derived 
from Illumina's annotations for the HumanCNV370 panel (Illumina Inc.). SNP allele 
frequencies in the Finnish population were calculated from control genotypes of 265 healthy 
individuals provided by the Nordic Centre of Excellence in Disease Genetics consortium. 
In study II, a multipoint parametric linkage analysis with MERLIN (v 1.1.2) (Abecasis et al., 
2002) was performed with four patients (XI-3, XII-4, XII-5 and XII-6). Problematic 
genotypes were wiped from the Merlin linkage files as described in study I. Recessive 
inheritance model with full penetrance and no phenocopies was used for autosomes along 
markers spaced at 0.25 cM intervals. Marker positions were derived from the HapMap phase 
II genetic map and SNP allele frequencies from the HapMap phase II data set of the CEPH 
(Utah residents with ancestry from Northern and Western Europe) population (CEU). 
Stretches of markers with a LOD score over three were extracted from the results and merged 
if distance between consecutive stretches was less than 1 cM.  
In study II, SimWalk2 (v2.91) (Sobel and Lange, 1996) was used to calculate a parametric 
LOD score for the disease locus in chromosome 3 with the extended pedigree information. 
Three candidate disease-causing variants were Sanger sequenced from all the family members 
from whom DNA was available, and the genotypes of one of the variants were used in the 
two-point linkage. The disease allele frequency of 0.005 was used based on the allele 
frequencies in low-coverage sequencing data from the north-east of Finland (402 individuals). 
Linkage input files for SimWalk2 were generated with Mega2 (Mukhopadhyay et al., 2005). 
In studies I and II, linkage-compatible regions were further combined with consecutive 
homozygous genotypes in affected individuals in order to determine regions of recessive 
founder mutations. 
4.2.2 Gene expression analysis (II, III) 
Affymetrix GeneChip Human Exon 1.0 ST microarrays (Affymetrix)  were utilized to 
measure whole-transcriptome expression from peripheral blood of five patients and five 
healthy siblings in study II, and from 38 leiomyomas and the corresponding myometrium 
from 30 women in study III. The same leiomyoma and myometrium tissue samples were 
included in WGS (Table 1). 
In studies II and III, signal intensity data from the arrays was first RMA normalized using 
Brainarray custom CDF files for gene-specific annotation of the probes. 
In study II, Student’s t-test (two-tailed distribution, two-sample equal variance) and log ratio 
were calculated for each of the 36,354 genes examined with the array. Pathway enrichment 
analysis was calculated for the most significant genes with p-value <0.1 (n=831, 2.3% of all 
genes) with the Ingenuity Pathway Analysis (IPA) software (Build version 220217, Ingenuity 
Systems, Inc.). 
In study III, similarities between the gene expression of tumor samples were assessed using 
unsupervised hierarchical clustering analysis with the top 1% most variable genes (n=372) 
which were selected based on the coefficient of variation (ratio of the standard deviation to 
the mean) calculated across all tumor samples. Statistical testing with three-way analysis of 
variance (ANOVA) was performed to identify genes that were uniquely expressed in 
leiomyomas of different genetic background. False discovery rate (FDR) method was used to 
control p-values for multiple testing (Benjamini and Hochberg, 1995). Pathway enrichment 
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analysis for HMGA2/HMGA1 overexpressing samples was calculated for the most significant 
genes using p-value <0.1, and fold change <-1.4 or >1.4 cutoffs (n=440, 1.2% of all genes) 
with the Ingenuity Pathway Analysis (IPA) software (Build version 302937, Ingenuity 
Systems, Inc.). 
4.3 Fragment analysis 
In study I, additional genotyping was carried out using genomic DNA extracted from the 
paraffin embedded tissue samples of the two affected children (II-1 and II-3), and using the 
DNA samples of the family members included also in the SNP genotyping. Di-nucleotide 
microsatellite repeats for four regions with candidate genes were selected from the University 
of California, Santa Cruz (UCSC) Genome Browser (Human Mar. 2006 Assembly). Lengths 
of the di-nucleotide repeat units varied from 19 to 26. Primers to the selected microsatellite 
repeats were designed with Primer3 (v 0.4.0) (Rozen and Skaletsky, 2000). PCR amplification 
of the samples was done with AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster 
City, CA, USA). PCR products were prepared for fragment analysis by adding Hi-Di 
formamide, including GeneScan-500 LIZ size standard (Applied Biosystems). Fragment 
analysis run was performed at FIMM Genome and Technology Centre as a service. Fragment 
analysis results were analyzed with GeneMarker software (v 1.4) (SoftGenetics LLC, State 
College, PA, USA). 
4.4 Sequencing methods 
4.4.1 Whole-genome sequencing data analysis (II, III) 
In studies II and III, genomic DNA libraries were prepared and sequenced according to 
Illumina (Illumina Inc.) or CG (Complete Genomics Inc.) paired-end sequencing service 
protocols. The Illumina NGS data consisted of short-insert paired-end reads with 100 bp read 
length, and with at least 30-fold average sequencing coverage. CG sequencing service was 
conducted with 40-fold average coverage and with 90% call rate for diploid loci on the human 
reference genome (Build 37). 
WGS was performed on one patient’s (XII-1) sample in study II, and on 38 leiomyomas and 
the corresponding myometrium from 30 women in study III (Table 1). Twelve tumor-normal 
pairs in study III were sequenced with the Illumina NGS technology, and the rest of the WGS 
data were produced by CG. All WGS data were analyzed for SVs, CNAs, SNVs and indels. 
Variant calling was performed only for the Illumina WGS data as described next in section 
4.4.1.1. CG provided us with high confidence variant calls that were used as such in the data 
filtering described in section 4.4.1.2. Variants with high specificity were prioritized in all 
WGS data analyses. One tumor-normal pair in study III was sequenced with both Illumina 
and CG sequencing platforms to evaluate whether the variation calls were comparable 
between the platforms.  
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Table 1. Uterine leiomyoma and myometrium samples included in the whole-genome sequencing with 
Illumina and/or Complete Genomics (CG) in study III 
Tumor 
sample 
Normal 
sample 
MED12 mutation 
(somatic) 
FH mutation (
a
germline and 
b
somatic) 
CG Illumina 
M1m3 M1N c.130G>A, p.G44S wt x  
M4m3 M4N wt c.738+3A>G
b
, and LOH
b 
x  
M5m1 M5N c.131G>C, p.G44A wt x  
M12m1 M12N c.128A>C, p.Q43P wt x  
M17m1 M17N wt wt x  
M18m1 M18N wt wt x  
M29m2 M29N c.131G>A, p.G44D wt x  
M32m1 M32N wt c.715G>A, p.A239T
b
, and LOH
b 
x  
M32m8 M32N c.130G>A, p.G44S wt x  
M38m5 M38N wt wt  x 
M44m1 M44N wt wt  x 
M44m2 M44N wt wt  x 
M49m1 M49N c.131G>C, p.G44A wt x  
M68m1 M68N c.131G>A, p.G44D wt x  
MY1m1 MY1N wt wt x  
MY9m3 MY9N c.100-5_c.130del36, 
loss of splice acceptor 
wt x  
MY10m3 MY10N wt wt x  
MY16m1 MY16N c.130G>T, p.G44C wt x  
MY18m1 MY18N c.130G>A, p.G44S wt  x 
MY18m2 MY18N wt wt  x 
MY18m3 MY18N wt wt  x 
MY22m1 MY22N wt wt x  
MY23m1 MY23N c.138_152del15, 
p.N47_V51del 
wt  x 
MY23m2 MY23N wt wt  x 
MY23m3 MY23N c.107T>G, p.L36R wt  x 
MY23m4 MY23N wt wt  x 
MY24m3 MY24N wt wt x  
MY29m1 MY29N c.131G>T, p.G44V wt x  
MY30m1 MY30N wt wt x  
MY33m2 MY33N c.100-8T>A, 
p.E33_D34insPQ 
wt x  
MY45m5 MY45N c.100-8T>A, 
p.E33_D34insPQ 
wt x  
MY46m1 MY46N wt wt x  
MY47m1 MY47N wt wt x  
MY48m1 MY48N wt wt x  
MY64m1 MY64N wt wt x x 
MY64m2 MY64N c.130G>C, p.G44R wt  x 
B7m6 B7N wt c.671_672delAG, p.E224fs
a
, and 
LOH
b
 
x  
N7m1 N7N wt c.1027C>T, p.R343X
a
, and LOH
b 
x  
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4.4.1.1 Variant calling 
SVs were detected with BreakDancerMax (version 1.2) (Chen et al., 2009) from the ELAND 
alignments provided by the Illumina paired-end sequencing service. Leiomyoma tumor SVs 
were called with more stringent criteria requiring higher mapping quality score (-q 65) and 
more discordant reads (-r 4) than in the normal myometrium SV calls (-q 1 -r 1).  
The ELAND alignments were realigned with the GATK IndelRealigner using target intervals 
that were created around dbSNP 135 variations and around initial variant calls produced by 
the GATK UnifiedGenotyper (DePristo et al., 2011). Duplicate reads were excluded with 
Picard Tools MarkDuplicates (http://picard.sourceforge.net) from the Illumina WGS data 
before detection of somatic SNVs, indels and CNAs with VarScan 2 (Koboldt et al., 2012). 
SNVs and indels were called at sites with a minimum coverage of 10 in both tumor and 
normal sample. Raw copy number data in 500 bp windows were smoothed and segmented 
requiring at least 2500 bp regions of equal copy numbers in circular binary segmentation 
algorithm. Copy number ratios were normalized against the average of all segments of a 
sample. 
4.4.1.2 Data filtering and annotation 
In study II, high confidence SV calls, and homozygous single nucleotide and indel variations 
in protein coding genes were extracted from the CG data within the homozygous regions 
shared between the six patients. Sequencing data from the north-east of Finland (402 
individuals, low-coverage data), from the 1000 Genomes project (phase 1) and from in-house 
NGS controls (191 Finnish individuals) were used to filter out homozygous variations 
detected in non-affected individuals. After control filtering, functional effects of the protein 
coding missense changes were predicted with PolyPhen-2 (v2.2.2r398) (Adzhubei et al., 2010) 
HumVar-trained models, and variations predicted to be benign were excluded. 
In study III, the BreakDancer results were filtered to include tumor SV calls in which either 
plus or minus strand coverages were at maximum of 60 reads at both breakpoints. This was 
performed to discard regions with suspiciously high sequencing depth indicative of repetitive 
and problematic genomic regions. Both Illumina tumor SV and CG somatic high confidence 
SV calls were filtered against (i) all Illumina normal myometrium SV calls, (ii) all CG normal 
myometrium SV calls, (iii) DGV variants (Release Date 2012-03-29), (iv) Segmental Dups 
(UCSC track table) (Bailey et al., 2001), and (v) Hi Seq Depth regions (UCSC track table) 
(Pickrell et al., 2011). In the filtering steps (i), (ii) and (iii), the type of SV and the locations 
of the both breakpoints flanked by 1 kb up- and downstream had to match for a tumor SV call 
to be filtered out. In steps (iv) and (v), a tumor SV call was filtered out, if at least one of the 
breakpoints was located within a 1000 bp window up- and downstream from repetitive 
genomic DNA defined by segmental duplications and regions of high sequencing depth. 
Despite the five systematic filtering steps, Illumina tumor SV calls contained breakpoints 
within repetitive DNA regions and within regions with discordant reads in the paired 
myometrium samples which were not called by BreakDancer. Furthermore, 84% percent of 
Illumina tumor SV calls were visually assessed and excluded as false positives after the 
systematic filtering. Canonical transcripts in Ensembl version 69 were used to define genes 
recurrently affected by SV breakpoints within or at maximum 250 kb upstream/downstream 
of TSS. 
In study III, copy number segments with tumor-normal ratio <0.3 were assessed as double 
deletions, 0.3-0.8 as deletions, 1.2-1.7 as duplications and 1.7-2 as triplications. No high level 
amplifications were observed. Regions ≤2 kb apart were merged, and regions overlapping 
gaps in the human genome assembly (UCSC Gap track table) were removed. Segments less 
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than 100 kb were filtered out. Ensembl version 69 annotations were utilized for mapping 
genes within CNA segment calls.  
In study III, somatic Illumina and CG point mutation and indel calls were filtered against all 
variant calls from the corresponding myometrium samples (n=30), 93 Finnish individuals 
from the 1000 Genomes Project (phase 1), rs-coded SNPs from the dbSNP (Build 132), and 
157 in-house NGS controls. Depth of coverage at a variant site had to be at least 6, and the 
percentage of mutated reads had to be at least 20. We chose the minimum variant score 
thresholds 29 for Illumina and 94 for CG based on previous validation experiments of MED12 
and FH mutations, and based on comparison of the common variations in the one sample 
sequenced with both platforms. Only protein coding variants of the canonical transcripts 
downloaded from Ensembl version 69 were considered. If a gene displayed a SNV or indel 
call more than once in our tumor series with scores above the thresholds, the call was subject 
for verification by Sanger sequencing. 
4.4.1.3 Detection of interconnected complex chromosomal rearrangements 
Complex chromosomal rearrangements (CCRs) were assessed using a computational method 
utilizing somatic SV and CNA calls. For each tumor, an event graph with nodes and edges 
was constructed as described in Figure 3 (see also Figure 1A and 1B in the original 
publication III).  
 
Figure 3. Event graph of somatic structural variations (SVs) in tumor M29m2. Nodes in the graph 
represent DNA double-strand break ends either left (head) or right (tail) of a breakpoint. Colors of the 
nodes represent different chromosomes. Nodes are connected by blue edges (i) if break ends are 
connected to each other by a SV call of discordant read-pairs, or by red edges (ii) if break ends in head 
and tail orientation are at most 1000 bases apart (numbers refer to the distance between heads and 
tails). The distance between a head and a tail was decreased by the length of deletion calls if found to 
be located between heads and tails. In this tumor, one component consisting of eight connected nodes 
created through four DNA double-strand breaks was identified in chromosome 4 (red nodes) and 
called as an interconnected complex chromosomal rearrangements event. 
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Components consisting of connected nodes were identified from each graph. After manual 
assessment of components, a CCR event was called only for samples with a minimum of six 
break ends that were interconnected. 
4.4.1.4 Assessment of clonally related leiomyomas 
Based on the mutation status of MED12, we selected to study additional tumors from four 
individuals (M29, M38, M68, and MY18) which were not included in WGS but were 
potentially clonally related. Each of these individuals had at least one lesion included in WGS 
from which unique somatic markers were selected for Sanger sequencing. Altogether 19 
leiomyomas were examined: 5 leiomyomas with wild type MED12 from patient MY18, 4 
leiomyomas with wild type MED12 from patient M29, 2 leiomyomas with wild type MED12 
from patient M38, and 8 leiomyomas with the same MED12 mutation (c.131G>A, p.G44D) 
from patient M68. 
4.4.2 PCR and Sanger sequencing (I, II, III) 
PCR primers were designed with web-based tools (Rozen and Skaletsky, 2000). In study I, 
the entire coding region or the two mutation sites of the candidate gene, growth/differentiation 
factor 1 (GDF1), were Sanger sequenced from the blood samples or from the paraffin 
embedded tissue samples, respectively. In study II and III, candidate SNVs and indel calls 
detected in the WGS data were verified by Sanger sequencing. In study II, cDNA samples of 
patients and controls were Sanger sequenced to detect splicing defects in two genes with 
candidate mutations. In study III, sample MY64m1 was in WGS with both Illumina and CG 
sequencing platforms, and all 32 SV calls found by either or both of the platforms were 
validated by Sanger sequencing. To assess the platform specific true positive rate, final SV 
calls from Illumina samples MY18m2 and MY18m3, and CG sample MY47m1 were also 
subjects for validation. 
PCR amplification was performed using AmpliTaq Gold DNA polymerase (Applied 
Biosystems) or Phusion DNA polymerase (Finnzymes, Finland). In study I, a modified 
reaction mixture from Expand Long Template PCR system (Roche Diagnostics, Germany) 
with GC-Melt Reagent (Clontech, Palo Alto, CA, USA) was used according to Joensuu et al. 
(Joensuu et al., 2007) for fragments with high guanine-cytosine content. The PCR products 
were purified using the ExoSAP-IT PCR purification reagent (USB Corporation, Cleveland, 
OH, USA), and the sequencing reactions were performed utilizing the Big Dye Terminator 
v.3.1 kit (Applied Biosystems). Electrophoresis was performed on a 3730xl DNA Analyzer 
(Applied Biosystems) at FIMM Genome and Technology Centre (Helsinki, Finland). The 
sequence graphs were analyzed manually or with the Mutation Surveyor software (versions 
3.24 and 3.30, Softgenetics, State College, PA, USA). 
4.5 Registry-based data analysis 
4.5.1 Systematic clustering of patients (IV) 
For each tumor type, systematic clustering was performed based on family name at birth 
(denoted as N-clusters), and combination of both municipality of birth and family name at 
birth (MN-clusters). The observed number of patients (O) with each tumor type in FCR was 
calculated in a stratum defined by municipality (M) (in case of MN-clusters only), family 
name (N), sex and year of birth. To estimate the expected number of cases (E) in each stratum, 
gender and birth-year specific number of cases of the tumor type in question were calculated 
from the NPR-linked subset of FCR. This number of cases was multiplied with the proportion 
of persons in each stratum in the entire population of the same gender and year of birth 
calculated from the NPR database. The stratum-specific observed and expected numbers were 
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added up over the gender and birth-year categories. O/E ratios were calculated for each N and 
MN category, and their 95% confidence intervals were defined assuming a Poisson 
distribution of observed numbers. 
4.5.2 Estimating familiality with cluster score (IV) 
To estimate the familial occurrence of various tumor types, a cluster score was calculated for 
MN-clusters, which were more likely representing true families than N-clusters. For each 
tumor type i, we selected clusters with the lower limit of confidence interval (CI-low) greater 
than or equal to α and calculated the number of patients (Xiα) in these clusters.  
The cluster score of tumor type i was defined as Xiα divided by the total number of patients 
with the same tumor type (Yi) per 100,000 persons in Finland. To estimate whether Xiα/Yi 
was different than the expected ratio YiXα/Y, where Xα/Y is the respective ratio over all tumor 
types in Finland (Xα/Y=0.0029 for α=10), two-sided Poisson test was calculated with 95% 
confidence level. The p-values were adjusted for multiple test comparisons with FDR method 
(Benjamini and Hochberg, 1995). 
4.6 Ethical issues 
Studies I and II were approved by the appropriate ethic review committees (Dnro 
310/E7/2000, Dnro 55/07/2000 and No. 110/2010), the respective clinical researchers as 
principal investigators. Written informed consent was received from the patients or from the 
patients’ parents or guardians, and from the healthy individuals in studies I and II. Three 
series of uterine leiomyoma samples were utilized in study III. The first series (denoted as “M” 
patients) consisted of samples from anonymous patients included in the study with the 
approval of the director of the appropriate health care unit. The second series (denoted as 
“MY” patients) and third series (denoted as “B” and “N” patients with the HLRCC syndrome) 
consisted of samples from patients with an acquired informed consent.  
Tumor patient data and sample collection procedures were evaluated and approved by the 
Ministry of Social Affairs and Health in Finland (Dnro 53/07/2000) and subsequently by the 
National Institute for Health and Welfare (THL/1071/5.05.00/2011). 
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5 Results 
5.1 Identification of GDF1 mutations in right atrial isomerism (I) 
Genome-wide SNP genotyping and linkage analysis of the parents, one healthy child and 
three affected children revealed 15 genomic regions compatible with recessive inheritance 
(Table 2). All of the fifteen loci had the maximum LOD score of 1.33. The longest 
homozygosity within the linkage-compatible regions was on chromosome 7 overlapping the 
centromere. The physical and genetic length of the homozygous region was 9.3 Mb and 1 cM, 
respectively, reflecting the low recombination rate of the centromeric region. Other 
homozygous regions did not exceed 1 cM; thus parents were likely carrying different founder 
mutations. Candidate-gene approach was chosen for prioritization of the regions, and four of 
the linkage-compatible regions included genes involved in the left-right axis development in 
model organisms (Table 2) (Levin, 2005; Okumura et al., 2008; Shen, 2007). 
Table 2. Linkage-compatible regions and positional candidate genes in study I 
Chr Start position 
(Mb)
a 
End position 
(Mb)
a 
Region 
length 
(Mb)
 
Region 
length 
(cM)
 
Candidate genes in 
model organisms 
HGNC 
Symbol 
1 68.46 94.20 25.7 21.96 Pcl-2 in chick MTF2 
3 0.07 5.81 5.7 16.65   
4 59.49 86.38 26.9 18.94   
5 166.88 168.25 1.4 2.84   
6 56.40 85.21 28.8 12.79   
7 33.67 45.53 11.9 13.83 Myosin31DF in D. 
melanogaster 
MYO1G 
7 57.40 88.48 31.1 21.76 Hgf in chick HGF 
8 6.40 10.53 4.1 7.80   
9 33.62 38.77 5.1 5.16   
9 76.32 92.29 16.0 23.82   
14 78.06 78.08 0.02 0.02   
17 77.29 81.04 3.7 12.71   
19 13.33 23.48 10.1 14.45 Gdf-1/Vg-1 in 
mouse/frog, Notch 
in mouse/zebrafish 
GDF1, 
NOTCH3 
19 55.97 59.08 3.1 5.61   
22 17.08 19.03 2.0 6.87   
a 
Genomic coordinates were converted from Build 36 to Build 37 with liftOver tool.  
The fragment analysis of di-nucleotide microsatellite repeats from additional two affected 
individuals excluded three of the four candidate loci. All five affected children were shown to 
share the same alleles within the linkage-compatible region on chromosome 19 (Figure 4). 
This region contained two candidate genes: NOTCH3 and GDF1. Autosomal dominant 
NOTCH3 mutations had been identified in patients with cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (MIM #125310). GDF1 had 
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previously been reported to be involved in the left-right patterning in mice with targeted 
homozygous deletion of the region encoding the mature Gdf1 (Rankin et al., 2000). 
Sanger sequencing of the protein coding regions of GDF1 (NT_011295.11) revealed two 
truncating mutations that segregated with the RAI phenotype in an autosomal recessive 
manner (Figure 4). The first mutation resided in exon 8 and caused a premature stop codon 
(c.681C>A, p.C227X). The second mutation was an insertion of cytosine (c.909insC) in exon 
8 leading to a frameshift and truncation (after 22 residues) (see Figure 2 and 3 in the original 
publication I). The father and the mother were healthy heterozygous carriers of the nonsense 
and the frameshift mutation, respectively. Affected children (II-1, II-2, II-4, and II-6) were 
compound heterozygotes for the two mutations in sequencing. The fifth affected child (II-3) 
was also carrying the mutations based on the microsatellite haplotypes, although DNA 
extracted from the paraffin embedded specimen was not of sufficient quality for successful 
sequencing. The healthy children displayed no mutations in GDF1. 
 
Figure 4. Family pedigree and haplotype analysis from the linkage-compatible region on chromosome 
19. The haplotypes associated with the nonsense mutation and with the insertion in GDF1 are colored 
blue and red, respectively. Plus denotes mutation and minus wild type allele on the mutation sites. 
Selected SNP genotypes are derived from Illumina’s genotyping panel. Microsatellites are named 
according to the chromosome number and physical positions in the human reference genome Build 36 
(hg18), and scored from 1 to 4 based on the ordered lengths of the PCR fragments. Squares denote 
men and circles women, solid symbols affected children, symbols with a dot healthy mutation carriers, 
and open symbols unaffected children. ND: not determined. 
The mutation sites identified in the family were screened in anonymous blood donors from 
the Finnish and UK populations. Among 346 Finnish blood donors, we found two 
heterozygous carriers of the insertion (c.909insC) and one heterozygous carrier of the 
nonsense mutation (c.681C>A, p.C227X). The whole coding region of GDF1 was sequenced 
from these individuals and no other variations were characterized. Among 271 control 
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samples from the UK population, one carrier of the nonsense mutation was found confirming 
the prevalence of the mutation outside Finland. 
In order to study the phenotypic effects of heterozygous GDF1 mutations further, healthy 
siblings of the parents and Finnish CRC patients were examined for the two mutations by 
Sanger sequencing. Three siblings of the mother carried the insertion without any indication 
of heart disease when their health status was interviewed. Among 278 CRC patients, one 
carrier of the insertion was found, and one patient had a heterozygous 11 bp deletion in GDF1 
(c.793_803delGGCGCTTGTCG). Although GDF1 is a player in the transforming growth 
factor beta (TGFβ) signaling pathway and binds to Activin receptors (Cheng et al., 2003), 
truncating mutations in GDF1 do not seem to predispose to CRC (Fisher´s exact test, two-
tailed p-value=1). The clinical records of the two CRC patients heterozygous for the 
frameshift mutations in GDF1 revealed normal cardiac development as evaluated by cardiac 
ultrasound in one and coronary bypass operation-related examinations in the other.  
5.2 Genetic mapping of severe intellectual disability syndrome (II) 
Six ID patients in four separate core families were identified by clinicians L. Pajunen and E. 
Rahikkala. The patients had developed a highly similar syndromic form of severe ID of 
unknown etiology, described in detail in the patient descriptions of the original publication II. 
All eight healthy parents of the patients were shown to have a common ancestor that lived in 
the 17
th
 century (see Figure 1 in the original publication II), suggestive of recessive 
inheritance of a novel ID syndrome. Four patients from two core families were utilized in the 
initial genome-wide linkage analysis. The longest recessively inherited region was on 
chromosome 3 encompassing 8.5 cM with the overall LOD score >3 (Figure 5). The second 
longest linked region was 3.5 cM and located also on chromosome 3. Homozygosity mapping 
of the SNP genotyping data of all six patients revealed an 11.5 Mb (chr3:42417576-53886650, 
5.2 cM) stretch of homozygosity within the longest linked region at 3p22.1-3p21.1 (see 
Figure 3A in the original publication II).  
 
Figure 5. Chromosome 3 displayed the longest region compatible with recessive inheritance of a 
novel intellectual disability syndrome at positions 64.3-72.8 cM. Y-axis represents the logarithm of 
odds (LOD) score calculated from the SNP genotyping data of four patients by the MERLIN 
parametric linkage analysis program. 
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No SVs were found at 3p22.1-3p21.1 in the WGS data of one of the patients. However, the 
data revealed three rare homozygous SNVs or indels within the locus that were in silico 
predicted to be probably protein damaging or causing errors in the splicing of protein coding 
genes (Table 3). All homozygous variants were shared by the six patients as validated by 
Sanger sequencing. The parents were heterozygous carriers, and the healthy siblings were 
either heterozygous or wild type. The Sanger sequencing results were utilized in the single 
point parametric linkage by SimWalk2. The information from the extended pedigree resulted 
in the final LOD score of 11 for the homozygous locus at 3p22.1-3p21.1. 
Table 3. Homozygous variations found at 3p22.1-3p21.1 in whole-genome sequencing after filtering 
and validated in all six patients by Sanger sequencing in study II 
HGNC 
symbol 
Variation
a 
Effect UniProtKB 
accession 
Protein change PolyPhen-2
 
I
 
II
 
III 
P4HTM 3:49042479 
G>A 
splice site 
defect 
Q9NXG6-1 R296S+ 297_358del - 5 1 - 
  missense Q9NXG6-3 R358Q probably 
damaging 
   
USP4 3:49323756_ 
49323758 
delCTC 
splice site 
defect 
Q13107-1 G658del, 
G658_E659del 
- 6 - - 
  splice site 
defect 
Q13107-2 G611del, 
G611_E612del 
-    
TKT 3:53269087 
T>C 
missense P29401-2 I189V probably 
damaging 
3 7 1 
  missense P29401-1 I181V benign    
a
 Genomic coordinates from Build 37 
I No. of heterozygous carriers in the regional controls (402 individuals) 
II No. of heterozygous carriers in the 1000 Genomes project data (1092 individuals) 
III No. of heterozygous carriers in the in-house next-generation sequencing controls of Finnish origin (191 
individuals) 
An in-frame loss of exon 6 (c.888_1073del186, p.Arg296Ser+Val297_Arg358del) of the 
prolyl 4-hydroxylase transmembrane (P4HTM) transcript (NM_177939.2) was detected in the 
patients’ blood derived cDNA (see Figure 3B in the original publication II). The effect was 
compatible with the defective 5’ splice site recognition and exon definition (Berget, 1995). 
The other known transcript of P4HTM with the presumed p.Arg358Gln change could not 
been detected in the blood. The homozygous deletion at a splice site of the ubiquitin specific 
peptidase 4 (USP4) transcripts (NM_003363.3 and NM_199443.2) produced two new 
transcripts through alternative 3’ splice site recognition: one with a 3 bp loss, 
c.1973_1975delGAG (p.Gly658del), and another with a 6 bp loss, c.1973_1978delGAGAAG 
(p.Gly658_Glu659del) (see Figure 3C in the original publication II). The third segregating 
homozygous variation affecting transketolase (TKT) caused protein changes p.Ile181Val 
(isoform 1, NP_001055.1) and p.Ile189Val (isoform 2, NP_001244957.1) which were benign 
and probably damaging, respectively. The isoform 2 of TKT has an alternative sequence of 8 
amino acids at the position 146 of the isoform 1, but how this alternative sequence affects the 
prediction remains ambiguous. 
The variants displayed 0.3-0.7% allele frequencies in the low-coverage WGS data derived 
from 402 individuals from the same region as the patients (Table 3). No homozygotes were 
found among any of the controls. We also studied the three candidate variants in additional 15 
patients from the north-east of Finland, and one deceased ID patient identified in the extended 
pedigree with severe ID of unknown etiology. All 16 patients presented with varying degree 
of compatibility with the novel syndrome. None of these patients carried the candidate 
sequence changes. 
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An enzyme assay showed normal TKT activity in the patients’ lymphoblasts as compared to 
non-affected controls. Elevated levels of sugars and polyols were noted in one patient’s urine 
and plasma as described earlier in ribose-5-phosphate isomerase (RPI) deficiency (Huck et al., 
2004). However, other patients had no change in sugar and polyol levels. Immunoblotting and 
real-time PCR experiments were performed to study the abundance of P4H-TM and hypoxia-
inducible factor-1 alpha (HIF-1α) and the expression of HIF-1α target genes in normoxic or 
hypoxic conditions in the patients’ lymphoblasts as compared to healthy siblings. The 
P4HTM transcript with the loss of exon 6 showed reduced induction in hypoxia, but the P4H-
TM protein levels were unchanged in the patients’ lymphoblasts. The HIF-1α protein levels 
and expression of the HIF-1α target genes were also unchanged (see Supplementary Figure 2 
in the original publication II). The experiments were done in collaboration with researchers 
from University of Oulu (Finland) and VU University Medical Center (Amsterdam, the 
Netherlands) and are described in detail in the original publication II. 
In gene expression analysis from the blood, the two most significantly altered pathways in 
five patients as compared to five healthy siblings were relaxin signaling and CREB [cyclic 
adenosine monophosphate (cAMP) response element-binding protein] signaling in neurons. 
Also cAMP-mediated signaling and G-protein coupled receptor signaling were among the 
five most significantly altered pathways. USP4 has been shown to regulate a G-protein 
coupled receptor at the cell surface (Milojevic et al., 2006), which could be an upstream event 
leading to the altered cAMP-mediated and CREB signaling. However, we could not detect 
changes in cAMP concentrations with immunoassay kit, or in the protein levels of 
phosphorylated CREB and total CREB with immunoblotting (see Supplementary Figure 3 in 
the original publication II). The immunoassay and immunoblotting experiments were 
performed as described earlier (Tuominen et al., 2014) using protein extracts from 
lymphoblastoid cell lines of patients as compared to healthy non-carrier siblings. 
5.3 Molecular genetic characteristics of uterine leiomyomas (III) 
5.3.1 Landscape of somatic alterations and complex chromosomal 
rearrangements 
The previously validated MED12 and FH mutations (Table 1 in section 4.4.1) were the only 
somatic SNVs or indels recurrently affecting protein coding genes in the set of 38 
leiomyomas included in WGS. The simple chromosomal rearrangements that were described 
previously in the literature were detected also in our WGS data. The large-scale deletions 
causing LOH on chromosome band 1q43 at the FH locus were detected in four tumors with 
germline (N7m1 and B7m6) or somatic (M32m1 and M4m3) FH mutation (Table 1 in section 
4.4.1). Three tumors displayed the balanced t(12;14)(q15;q24) translocation and four tumors a 
large deletion on chromosome 7q-arm.  
The WGS data revealed abundant complex chromosomal rearrangements in uterine 
leiomyomas. Rearrangement breakpoints were located near breakpoints from other 
rearrangements or deletions assessed as chained event graphs (see Figure 1A and 1B in the 
original publication III). These interconnected CCRs were detected most frequently in tumors 
lacking MED12 and FH mutations (12/16), in three MED12-mutant tumors (3/16) and in none 
of the FH-deficient tumors (MED12 and FH mutant tumors vs. other tumors, Fisher´s exact 
test, two-tailed p-value <0.001). Five tumors with CCR events (MY10m3, MY23m4, 
MY46m1, MY47m1 and MY64m1) displayed 20 or more breakpoints in a single 
chromosome; thus they were typical examples of the recently described chromothripsis 
phenomenon (Stephens et al., 2011). 
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Sanger sequencing of all SVs from three leiomyomas with a high number of breakpoints 
verified CCR events. Validation showed 93% (64/69) and 98% (99/101) true positive rate for 
SVs detected in the Illumina and CG data, respectively. To compare data quality between the 
two different platforms and to assess false negative rate, MY64m1 was sequenced using both 
Illumina and CG. Altogether 32 SV calls were found with both platforms and validated. Only 
eight and five validated SV calls were found to be uniquely called in the Illumina and CG 
data, respectively. 
CCR events in two tumors had created rearrangements between chromosome 12 and 14 
combining the 5´ end of the RAD51B gene with full length HMGA2, a phenomenon which is 
detected likewise in the balanced t(12;14)(q15;q24) translocations. Three other tumors 
displayed also CCR events resulting in rearrangements at HMGA2 or HMGA1 loci, but 
without RAD51B involvement. One of these rearrangements removed the 3’ UTR of HMGA2, 
which is the target sequence for the microRNA repressor let-7b, providing a mechanism for 
upregulation of HMGA2 (Mayr et al., 2007). The oncogenic upregulation was detected in all 
tumors with HMGA2/HMGA1 rearrangements in the gene expression data. The 
rearrangements lacking RAD51B involvement caused the lowest HMGA2 upregulation, 
suggesting that RAD51B is accompanied by an effective enhancer for HMGA2. Based on 
deletion and breakpoint mapping at the RAD51B locus, we pinpointed the minimal region 
containing a possible enhancer for HMGA2 to chr14:68217257-68760115 (see Supplementary 
Figure 6 in the original publication III). 
Recurrent chromosomal changes were detected also at the COL4A5/COL4A6 locus on 
chromosome Xq22 in tumors without MED12, FH or HMGA2/HMGA1 alterations. This locus 
is known to be disrupted in persons with Alport syndrome and diffuse leiomyomatosis (ATS-
DL, MIM #308940). A characteristic simple deletion reported previously in ATS-DL patients 
was detected in one uterine leiomyoma (see Figure 3A in the original publication III). In two 
tumors, CCRs resulted in the fusion of the 3´ends of the two collagen genes (see Figure 3B 
and C in the original publication III). These three tumors showed on average 5.6-fold 
upregulation of the IRS4 gene which is located adjacent to COL4A5.  
In tumor MY47m1, the CCR event disrupting COL4A5/COL4A6 was detected only in CG 
somatic low confidence SV calls, and confirmed by Sanger sequencing. This tumor had the 
highest number of breakpoints and chromothripsis (Figure 6A). One of the breakpoints in 
chromosome 11 located 215 kb upstream of the cell cycle progression gene CCND1 
(encoding cyclin D1) that was upregulated by 16-fold as compared to the corresponding 
myometrium. Because loss of p53 was earlier associated with increased frequency of 
chromothripsis (Rausch et al., 2012), we studied carefully all the breakpoints that would 
disrupt TP53. One tumor (MY10m3) had a complex rearrangement disrupting one allele of 
TP53 and a chromothripsis-like remodeling event on chromosome 17. The SV hit both TP53 
and NF1 genes at the same time as validated by Sanger sequencing. 
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Figure 6. Circos plots of somatic structural variations and copy number alterations detected in 
samples MY47m1 (A) and MY23m4 (B) with complex chromosomal rearrangements resembling 
chromothripsis. Chromosomes are organized circularly in the outer ring. Black lines in the circos plots 
indicate structural variations, and blue segments deletions. 
Some tumors contained more than one independent CCR event as shown by spatial or 
temporal difference of interconnected rearrangements. Two spatially separate CCR events 
were present in MY18m2 with equal discordant read frequency (see Figure 1C in the original 
publication III). The other event involved chromosomes 1, 2 and 20, and the other event 
involved chromosomes 12 and 14 creating the translocation between the HMGA2 and 
RAD51B loci. The same tumor also displayed a temporally separate CCR event involving 
chromosome 5 (see Figure 1D in the original publication III). Another tumor, MY23m4 
displayed two independent CCR events affecting both copies of chromosome 7 and the cut-
like homeobox 1 (CUX1) gene. The interconnected rearrangements in MY23m4 were 
affecting chromosome 2 and chromosome 7 in one event, and chromosome 5 and another 
copy of chromosome 7 in the other event (Figure 6B). 
The most recurrently affected gene by deletions and breakpoints was CUX1 on chromosome 
7q-arm (see Supplementary Figure 7 in the original publication III). The tumor MY23m4 with 
two independent CCR events, each disrupting one copy of chromosome 7, had the lowest 
expression of CUX1 among all tumors (see Supplementary Figure 5 in the original publication 
III). The tumors with CUX1 changes did not cluster together in hierarchical clustering 
analysis of gene expression data. Instead, the global gene expression profiling revealed three 
separate leiomyoma subgroups: MED12 mutation-positive, FH-deficient and 
HMGA2/HMGA1-overexpressing samples, which clustered in distinct branches (see Figure 2 
in the original publication III) as previously suggested in separate studies (Hodge et al., 2012; 
Mäkinen et al., 2011b; Vanharanta et al., 2006). Interestingly, the most up-regulated gene in 
MED12 mutation-positive tumors was RAD51B. Furthermore, tumors with HMGA2/HMGA1 
overexpression displayed upregulation of genes involved in the cell cycle G1/S checkpoint 
regulation, such as CCND1, CCND2, CCND3 and CDK6.  
5.3.2 Clonal origin of multiple tumors 
Several identical chromosomal changes were detected in the WGS data of two tumor pairs 
from two patients (MY18 and M44). The other tumor pair, MY18m2 and MY18m3, shared 
over 20 identical rearrangements which were not detected in the third tumor (MY18m1) that 
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was also included in the WGS experiment from the same patient. The other tumor pair, 
M44m1 and M44m2, shared nine identical rearrangements. MY18m2 and M44m1 had fewer 
SV calls detected on chromosome 5 and chromosome 7, respectively, as compared to their 
clonally related tumors MY18m3 and M44m2. However, these rearrangements were present 
in the aligned WGS reads of MY18m2 and M44m1 with lower discordant read frequency than 
the threshold used in the variant calling. In addition to chromosome 5 changes, MY18m3 had 
CNA calls on chromosomes 4 and 19 not called in MY18m2. Since chromosome 12 and 14 
changes as well as chromosome 1, 2 and 20 changes were detected in both MY18m2 and 
MY18m3 at similar levels, we considered the changes in chromosome 4, 5 and 19 to be only 
subclonally present in MY18m2, as detected by the calculation of average log2 copy number 
ratios (tumor versus normal) for the deleted regions (Table 5). This pattern of changes 
suggested MY18m2 to be a primary tumor from which a cell lineage with the subclonal 
somatic changes in chromosome 4, 5 and 19 had formed the secondary tumor MY18m3. 
Table 5. Average log2 copy number ratios for the deleted regions in the clonally related tumors 
MY18m2 and MY18m3 
Chromosome 4, a deletion on p-arm, subclonal in MY18m2, chr4: start-49,660,117 
Sample Average log2 ratio 
MY18m2 -0.141 
MY18m3 -0.577 
Chromosome 19, a deletion on q-arm, subclonal in MY18m2, 
chr19: 27,681,783-end 
Sample Average log2 ratio 
MY18m2 -0.117 
MY18m3 -0.484 
Chromosome 5, CCR related deletions, subclonal in MY18m2, 
chr5: 107,392,713-149,571,004 and chr5: 149,752,077-158,199,892 
Sample Average log2 ratio 
MY18m2 -0.162 
MY18m3 -0.715 
Chromosome 1, a CCR related deletion, chr1: 882,685-29,447,281 
Sample Average log2 ratio 
MY18m2 -0.718 
MY18m3 -0.722 
Chromosome 14, CCR related deletions,  
chr14: 39,424,193-43,740,449 and chr14: 63,744,555-68,216,937 
Sample Average log2 ratio 
MY18m2 -0.715 
MY18m3 -0.795 
 
To find additional tumors that were clonally related, Sanger sequencing of somatic point 
mutations was performed from tumors selected based on concordant MED12 mutation status. 
Three additional tumors (MY18m4, MY18m5 and MY18m6) from patient MY18 were shown 
to be clonally related to MY18m2 and MY18m3. Patient M38 had one additional tumor 
clonally related to the tumor M38m5. We did not find additional tumors of patients M29 and 
M68 to be clonally related to the tumors M29m2 and M68m1, which were included in WGS. 
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Altogether two tumors from patients M44 and M38, and five out of six tumors from patient 
MY18 were shown to be clonally related. 
5.4 Familial aggregation of tumor types in Finland (IV) 
Two systematic clustering efforts for 878,593 cases in the FCR database were performed: one 
based on tumor type, municipality of birth and family name at birth (MN-clusters), and 
another on tumor type and family name at birth (N-clusters). As a result, we identified 25,910 
MN-clusters and 12,695 N-clusters representing 183 tumor types (Figure 7). 
 
Figure 7. Procedure of the systematic clustering with the example of Kaposi sarcoma. Tumor types in 
the Finnish Cancer Registry (FCR) were defined by unique combinations of topography and 
morphology (topo-morpho) classifications. Patients with personal identity code (PIC) were linked to 
the National Population Registry (NPR). Eight percent of the patients clustered based on tumor type, 
municipality of birth and family name at birth (MN-clusters). MN-clusters with the strongest 
confidence, with the lower confidence limit (CI-low) greater than or equal to ten, were included in the 
cluster score calculation. Kaposi sarcoma patients clustered frequently in MN-clusters with CI-low≥10 
(3.5%) as compared to all patients in FCR (0.3%) and, thus, were subject for thorough genealogy work, 
which revealed eight families with two first-degree relatives diagnosed with Kaposi sarcoma. 
We considered only the most significant MN-clusters in the cluster score calculation that 
demonstrated our familial aggregation measure for the tumor types. Twenty tumor types, 
ranked according to cluster score, displayed FDR adjusted p-values less than 0.0001 (see 
Table 1 in the original publication IV). Among the top five tumor types showing strongest 
evidence for familial clustering were four phenotypes that have predisposition genes 
identified earlier. These included hemangioblastoma (cluster score 4.98), medullary thyroid 
carcinoma (cluster score 3.55), pancreatic neuroendocrine tumors (cluster score 1.40), and 
nephroblastoma (cluster score 1.26), which were indicative of patients with the Von Hippel-
Lindau syndrome (VHL, MIM #193300), Multiple Endocrine Neoplasia type 2 (MEN2A, 
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MIM #171400, and MEN2B, MIM #162300), Multiple Endocrine Neoplasia type 1 (MEN1, 
MIM #131100) and Wilms tumor 1 (WT1, MIM #194070), respectively. 
Kaposi sarcoma was the highest scoring tumor type for which prevalent predisposition gene 
mutations were not previously known. Relatives of the KS patients in the MN-clusters were 
traced back at least three generations to confirm kinship of the clustered cases. The genealogy 
revealed that 16 patients out of 23 (70%) were first-degree relatives within the MN-cluster, 
and most of these were found in clusters with CI-low≥10 (Figure 8). One of the families 
displayed five KS patients in two generations (see Figure 2 in the original publication IV). 
Three affected siblings in the family had the same family name at birth. One of them was born 
in a different municipality and, therefore, could be linked to the family through the respective 
N-cluster (Figure 8). An affected cousin was connected to the family through genealogy work, 
and the mother’s KS diagnosis was confirmed from radiotherapy records after it was reported 
by her daughter. 
 
Figure 8. Geographical distribution of the birth places of Kaposi sarcoma (KS) patients in clusters. 
Clustering was performed based on municipality of birth and family name at birth (MN-clusters), or 
based on family name at birth only (N-clusters). (A) Sixteen familial cases were identified through 
genealogy of MN-clusters. One case was connected to a family of two cases based on N-clustering. (B) 
Familiality could not be confirmed for 36 cases in MN- or N-clusters. Most of the KS patients in the 
clusters were born in the western part of Finland. Flags and pins are colored blue and red according to 
the lower confidence limit (CI-low) of the respective MN-clusters. 
The overall KS incidence was studied utilizing the small-area mapping method developed in 
FCR (http://astra.cancer.fi/cancermaps/suomi5308/). Patients were shown to accumulate to 
the Western Finland (see Figure 3 in the original publication IV), as also illustrated by the 
geographical distribution of the clustered KS cases (Figure 8). 
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6 Discussion 
Thorough clinical characterization of patients and good sample materials enabled successful 
research on various phenotypes conducted in this thesis (Figure 9). Congenital diseases in 
siblings with a clear phenotype present in infancy are usually indicative of inherited genetic 
conditions, such as in studies I and II. The sample materials from multiple affected and 
healthy individuals allowed the genome-wide studies on genetic causes of rare diseases in two 
families. In study III, pure fresh frozen tumor and myometrium tissue materials served as a 
basis for the molecular genetic study of uterine leiomyomas. Uterine leiomyomas display a 
good in vivo model of benign tumor growth, as multiple independent tumors can arise in 
single patients’ uterus without malignant degeneration.  
Finland and other Nordic countries have long traditions in nationwide population level 
registration. FCR is a unique database with complete population-based data of cancer 
incidences applicable for epidemiological studies (Pukkala, 2011; Teppo et al., 1994). In 
study IV, the registry-based data were utilized to identify new tumor predisposition 
phenotypes (Figure 9). Because every Finnish citizen has a PIC since the 1960s, the data 
linkage between FCR and NPR was possible, and birth municipalities and family names at 
birth could be retrieved for a large number of patients in FCR. Correspondingly, the parish 
records are a major resource for genealogical information on births, deaths and marriages 
since the 16
th
 century (Peltonen et al., 1999a), which was utilized successfully in the 
genealogy in studies II and IV. 
Traditional methods to identify Mendelian disease genes have included Sanger sequencing of 
positional candidate genes selected based on genetic mapping and relevance of the encoded 
proteins to the disease development (Figure 9). In study I, this research strategy was 
employed successfully, owing much to the numerous studies of left-right axis development in 
model organisms (Levin, 2005; Okumura et al., 2008; Shen, 2007). The introduction of NGS 
technologies during this thesis work allowed the search for novel candidate genes in study II, 
and the characterization of leiomyoma genomes in study III (Figure 9).  
Much work is still needed to improve sequence variant calling and delineation of disease-
causing variants from NGS data. Many NGS studies have failed to detect SV calls of certain 
size ranges, and combination microarray- and sequencing-based approaches are needed to 
capture all variation in an individual genome (Pang et al., 2010). Repetitive regions are 
problematic in alignment, and nearly 4% (~100 Mb) of the genome is considered poorly 
mappable with the current high-throughput and short read approaches (DePristo et al., 2011; 
Treangen and Salzberg, 2011). A large number of false positive calls is a considerable 
challenge especially in SV analyses of short read sequencing. We disregarded all SV calls that 
originated from problematic genomic regions in study III. It is possible that many true 
variants have also been missed in our WGS data analyses, and for more sensitive detection of 
all types of variants, several tools should be applied (Pabinger et al., 2014). Furthermore, 
assessment of disease-causing or disease-associated variants from a large number of 
background variants requires careful consideration in the era of NGS. In the studies of this 
thesis, specificity was prioritized as we tried to address the biological and etiological 
significance of the most prominent genetic causes of diseases in multiple individuals. False 
assignments are a substantial issue in disease genetics, and general recommendations have 
recently been given for assessment of causality of sequence variants. Most importantly, any 
novel gene should be implicated in disease only when genetic support from multiple 
independent cases can be provided (Figure 9) (MacArthur et al., 2014). 
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Figure 9. Summary of approaches for studying susceptibility phenotypes and genetic background of 
diseases. Genetic epidemiology studies the role of genetic factors in disease etiology and familial 
aggregation. Epidemiological measures can direct the selection of appropriate molecular genetic 
methods for identification of underlying genetic causes.  Any genetic change should be studied in 
multiple idependent patient and sample materials before final assessment of causality. The materials 
and methods used in the studies of this thesis are indicated with roman numbers. 
6.1 The role of GDF1 in isomerism and heart defects (I) 
Heterogeneity of laterality defects in human patients has complicated the identification of 
disease-causing genes, and no gene was unambiguously identified to follow autosomal 
recessive inheritance of RAI before study I was conducted. The assumption of autosomal 
recessive inheritance was justified in the study family, as there were five affected patients in 
one generation, including both males and females. Although the number of linkage-
compatible regions was high after the initial genome-wide analysis, positional candidate-gene 
approach reduced the number of interesting loci to four. The microsatellite genotyping 
confirmed one genomic region as a plausible disease locus with one candidate gene, GDF1. 
Two truncating mutations in GDF1, c.681C>A (p.C227X) and c.909insC, segregated with the 
RAI phenotype in an autosomal recessive manner in the family. The parents were healthy 
heterozygous carriers of one of the two mutations. Similar to the phenotype in the affected 
siblings in this study, Gdf1-/- mice have been shown to display a spectrum of laterality defects 
including complex cardiac defects and duplication of the right-sided pattern in the lungs (right 
pulmonary isomerism) (Rankin et al., 2000). Partial embryonic lethality of Gdf1-/- mice after 
E14.5 has been reported in two studies (Andersson et al., 2006; Rankin et al., 2000). Complex 
heart defects reduced the viability of the Gdf1-/- mice, resembling the poor prognosis of 
human patients with RAI (Eronen et al., 2013; Freedom et al., 2005). 
GDF1 belongs to the transforming growth factor beta (TGFβ) family of proteins with three-
dimensional cystine-knot conformation, which exist mostly as homo- or heterodimers (Sun 
48 
 
and Davies, 1995). The mature GDF1 consists of the residues from 254 to 372 and is formed 
from its larger precursor preproprotein after translation by proteolytic processing (see Figure 
3 in the original publication I). First the amino-terminal signal sequence directing the protein 
to secretion is removed, after which the propeptide is cleaved to release the active mature 
protein. The nonsense mutation, p.C227X, resides before the cleavage site, thus preventing 
the production of the mature protein, whereas the insertion, c.909insC, changes the mature 
protein product from the residue 303 onwards leading to a severely altered protein and 
truncation. After the insertion, three out of the six cysteines needed for the cystine-knot 
conformation are lost (see Figure 3B in the original publication I). 
Nodal is known to be one of the morphogens asymmetrically localized to the left side of the 
developing embryo by nodal flow. This is supported by the findings that loss of Nodal in the 
node causes disruptions in the subsequent molecular asymmetry and left-right patterning in 
mice (Brennan et al., 2002). Gdf1-/- embryos lacked expression of Nodal in the left half of 
early mouse embryo called left lateral plate mesoderm (LPM), suggesting that Gdf1 is 
required for the left-sided expression of Nodal (Rankin et al., 2000; Tanaka et al., 2007). 
Furthermore, Gdf1 has been suggested to enhance Nodal activity in the left LPM and, 
subsequently, to activate a known midline-specific gene, Lefty1 (Tanaka et al., 2007). 
Altogether, previous studies seem to support the essential role of GDF1 in the early left-right 
axis specification during embryogenesis. 
A previous report had examined 375 unrelated individuals with cardiac abnormalities for 
mutations in GDF1 (Karkera et al., 2007). They found eight heterozygous mutations, of 
which two (p.C227X and p.C267Y) were likely loss-of-function mutations. In addition to the 
p.C227X mutation that was also identified in our study, they found a heterozygous mutation 
(p.C267Y) changing the first cysteine needed in the cystine-knot formation. However, 
Karkera et al. (2007) had only studied patients but not their parents. Therefore, it is not 
known if any of the healthy parents were carriers of the mutation, contradicting their own 
suggestion that heterozygous loss-of-function mutations in GDF1 are causative for congenital 
heart defects (CHD). Our results from the blood donors, CRC patients and healthy parents and 
their siblings, who were confirmed not to have any history of heart defects, suggest that one 
loss-of-function mutation in GDF1 is not enough for the occurrence of CHD. Nevertheless, it 
is possible that the other six mutations found by Karkera et al. (2007) have dominant negative 
effect through dimerization or receptor binding in aberrant cardiac development. At least three 
of the mutations (p.S56P, p.P59T and p.A69T) reside in a proportion of GDF1 implicated in 
dimerization (Karkera et al., 2007; Sun and Davies, 1995). Gene dosage effect as an etiologic 
factor has been proposed in 4.3% of CHD cases that were shown to harbor rare CNVs in 
genes associated with cardiac malformations. Interestingly, one large gain has been observed 
in GDF1 in a CHD patient (Tomita-Mitchell et al., 2012). Combination of genetic and 
environmental factors may be required for the manifestation of cardiac anomalies, and further 
work is needed to investigate the possible role of heterozygous GDF1 mutations in CHD.  
Incidences of 0.67 and 0.49 per 10,000 live births for LAI and RAI, respectively, have been 
reported in the Canadian population (Lim et al., 2005). High rate of prenatal termination of 
pregnancies might lower the incidence of RAI among live births (Yan et al., 2008). In our 
study, we identified altogether 11 carriers of heterozygous truncating GDF1 mutations. The 
nonsense mutation (p.C227X) was identified in the Finnish and UK blood donors as well as in 
the study of Karkera et al. (2007), demonstrating the presence of the mutation also in the US 
population. Although the role of heterozygous GDF1 mutations in CHD remains 
contradictory, recessively inherited mutations in GDF1 seem clearly causative for the RAI 
phenotype in the study family, supported by the similar phenotype in knockout mice. Further 
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studies are warranted to examine the proportion of GDF1 mutations underlying RAI, which is 
one of the most severe forms of congenital cardiac defects (Eronen et al., 2013). 
6.2 Candidate genes of novel severe intellectual disability syndrome (II) 
Six patients with severe ID syndrome of unknown etiology originated from the same village 
from the north-east of Finland. The village is part of the late-settlement region inhabited by a 
well-characterized young isolate useful for identification of rare disease-causing variants 
(Jakkula et al., 2008). Consanguinity of the healthy parents of the patients could be 
ascertained by in-depth genealogy, which led us to suspect autosomal recessive ID, and a 
single origin genetic defect. In addition to delayed psychomotor development and hypotonia, 
abnormalities in the visual focusing and strabismus were noted in the patients. The phenotype 
included also coarsening of facial features and obesity suggestive of a storage disease and a 
deficiency in metabolism. 
Genome-wide analyses revealed a long 11.5 Mb stretch of consecutive homozygous SNP 
genotypes at 3p22.1-3p21.1 shared between all six patients. The locus showed a LOD score of 
11, confirming the autosomal recessive linkage. The WGS data of one of the patients allowed 
identification of three candidate genes, TKT, P4HTM and USP4 with potentially protein 
damaging sequence changes within the homozygous region. The variants were present with 
0.3-0.7% allele frequencies in the population-matched controls, and only heterozygous 
carriers were found in the control sets examined. None of the genes were earlier shown to be 
mutated in ID phenotypes. 
TKT, which is a ubiquitous thiamin-dependent enzyme linking the pentose phosphate 
pathway (PPP) and glycolysis (Schenk et al., 1998) has a clear metabolism-related function. 
The identified missense change (p.Ile181Val in isoform 1 and p.Ile189Val in isoform 2) 
affects a conserved isoleucine residing in a beta sheet structure of the protein (Mitschke et al., 
2010). A patient with a deficient activity of RPI, another PPP enzyme, was previously 
described with leukoencephalopathy, psychomotor retardation, epilepsy and a slow 
neurological regression (MIM #608611) (Huck et al., 2004). The symptoms of our patients 
were similar except for leukoencephalopathy. Huck et al. (2004) had reported compound 
heterozygous mutations (frameshift and missense type changes) in the RPI gene, decreased 
activity of the enzyme, and highly elevated levels of ribitol and D-arabitol in the brain and 
body fluids of the patient. We tested the enzyme activity of TKT from the patients’ 
lymphoblasts, and polyol levels of the patients’ urine and plasma, but could not detect 
consistent differences as described in the RPI deficiency. Knockout of Tkt has been shown to 
be embryonic lethal in mice (Xu et al., 2002), suggesting that the patients’ ID syndrome is not 
caused by total loss of TKT. 
The variant at the splice site of P4HTM had the most dramatic effect on protein sequence, as 
the in-frame loss of exon 6 (p.Arg296Ser+Val297_Arg358del) was detected in patients’ blood. 
P4H-TM has been reported to hydroxylate HIF-1α that is targeted for degradation in 
normoxic cellular conditions (Koivunen et al., 2007). HIF-1α and HIF target genes are 
important during early development of the brain (Trollmann and Gassmann, 2009). Unlike 
other known prolyl 4-hydroxylases, P4H-TM has a transmembrane domain and is localized to 
the endoplasmic reticulum membranes. The catalytically important C-terminal region of P4H-
TM contains two histidines and one aspartate that bind the Fe2+ (Koivunen et al., 2007). Two 
of these, His328 and Asp330, are lost due to the splicing defect causing complete loss of the 
proposed enzyme function. Interestingly, P4HTM expression seems to be highest in the 
central nervous system (BioGPS, expression profile of the 222125_s_at probeset) (Wu et al., 
2009), and in the eye and brain of Zebrafish (Hyvarinen et al., 2010). Although we could not 
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verify the suggested loss of P4H-TM activity in the patients’ lymphoblasts, the tissue-specific 
expression of P4HTM could explain the patients’ abnormalities in neural development and 
vision. The tissue-specific function of P4HTM should be studied with a mouse model, for 
example. 
The third candidate gene, USP4, displayed expression of two alternative transcripts with loss 
of one or two amino acids (p.[Gly658del,Gly658_Glu659del]) in the patients’ blood. USP4 
deubiquitinates target proteins, and has been shown to regulate expression of the Adora2a 
receptor, a Gs-coupled receptor at the cell surface of cultured hippocampal neurons (Milojevic 
et al., 2006). Signaling pathways that show significant enrichment of differentially expressed 
genes may provide evidence of the underlying genetic defect. Our expression analyses 
showed altered expression of genes that were enriched in the CREB, G-protein coupled 
receptor and cAMP signaling pathways. The three pathways regulate CREB transcription 
factors through cAMP signal transduction, and the enrichment could be related to the altered 
function of USP4 in regulating Gs-coupled receptors. CREB is a known player in certain 
neurodegenerative diseases, such as in Coffin-Lowry syndrome caused by mutations in the X-
chromosomal CREB protein kinase RPS6KA3 (MIM #303600) (Trivier et al., 1996) and in 
Rubinstein-Taybi syndrome caused mainly by de novo heterozygous mutations in CREB 
binding protein (MIM #180849) (Petrij et al., 1995). We could not detect alterations in the 
cAMP concentrations or in the CREB protein levels in the patients’ lymphoblasts, although 
the effect might be specific to CREB5, which was slightly downregulated in the expression 
analysis (p-value=0.08). Unfortunately, we could not get CREB5 antibodies to work in 
immunoblotting. 
Altogether, the novel ID syndrome might be a monogenic, digenic or trigenic disease specific 
to the haplotype of the three variants in homozygous form, although the possibility of a 
causative noncoding change in the 3p22.1-3p21.1 locus cannot be excluded based on this 
study. The frequency of the identified candidate variants in the north-east of Finland suggests 
that more patients with the same haplotype are likely present in the region. Additional fifteen 
patients with varying degree of compatibility with the ID patients of the study family were 
examined for the three variants with negative results. Further studies with a larger set of 
patients are warranted to clarify the role of the identified candidate genes in the development 
of severe ID. 
6.3 Genetic changes in development of uterine leiomyomas (III) 
The application of NGS and microarray technologies allowed us to characterize genomic 
alterations across a wide range of uterine leiomyomas. We selected tumors without MED12 
and FH mutations, as well as MED12-mutant and FH-deficient tumors, for the experiment. 
Somatic point mutations affecting protein coding genes were rare in the uterine leiomyomas. 
However, CCR events were detected in 15 tumors. Some CCR events had created 20 or more 
breakpoints in a single chromosome, while other CCR events displayed three breaks that all 
had occurred simultaneously. CCRs were inferred computationally from chained event graphs 
utilizing SV and CNA calls. Step-wise accumulation of DNA breakage and anomalous repair 
of break-end pairs seems an unlikely mechanism, as multiple repaired breakpoint junctions 
would have to be rebroken to form such interconnected rearrangements. The CCR events in 
the leiomyomas resembled the phenomenon of chromothripsis that was earlier associated with 
advanced cancers (Rausch et al., 2012; Stephens et al., 2011). 
Chromothripsis was first described as a catastrophic shattering of one or two chromosomes, 
and as a formation of clustered rearrangements and focal losses of DNA (Stephens et al., 
2011). The most likely mechanisms to explain chromothripsis include replication stress 
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caused by activated oncogenes at the G1/S phase of the cell cycle and mitotic errors (Jones 
and Jallepalli, 2012). Whether or not the CCR events in leiomyomas are formed through the 
same mechanism as chromothripsis remains to be studied. Compatible with the 
chromothripsis phenomenon, one leiomyoma with the most breakpoints displayed a CCR 
event causing activation of the CCND1 gene, which is a known regulator of the cell cycle 
G1/S transition. Although chromothripsis has been associated with TP53 mutations (Northcott 
et al., 2012; Rausch et al., 2012; Wu et al., 2012), we detected only one tumor with a TP53 
rearrangement that was created through a CCR event and no point mutations in TP53 in any 
of the leiomyomas studied. In some tumors, we could show that separate CCR events had 
occurred multiple times in a single tumor cell lineage. After the publication of study III, 
prostate tumors were also shown to harbor sequential CCR events similar to ours. The CCR 
events in a subset of prostate tumors also affected more than one or two chromosomes, and 
involved fewer breakpoints than detected in chromothripsis (Baca et al., 2013). 
CCRs seem to be a major cause of chromosomal alterations creating tissue-specific changes 
in tumors lacking MED12 and FH mutations (Figure 10). CCRs had produced the known 
rearrangements between the HMGA2 and RAD51B loci, or alterations of the 
COL4A5/COL4A6 locus in multiple tumors. CCRs are not expected to create these types of 
selective changes with such a high frequency as detected in the tumors in our WGS 
experiment; thus, CCR events must not be rare in precursor myometrial cells. Majority of the 
most dramatic remodeling events likely leads to apoptosis (Figure 10). 
Gene expression data could confirm oncogenic HMGA2 and HMGA1activation in all eight 
tumors with the upstream breakpoints of the respective genes. Similar to a previous study 
(Hodge et al., 2012), genes involved in the G1/S transition were dysregulated among 
HMGA2/HMGA1 overexpressing samples. The most frequent translocation partner, RAD51B 
was shown to provide HMGA2 with an effective enhancer. RAD51B is a DNA repair protein 
that is disrupted in leiomyomas by the rearrangements, and may have a role in maintaining the 
genome stability in myometrial cells.  
Three samples with the alterations of COL4A5/COL4A6 displayed a clear upregulation of 
IRS4. COL4A5 is located head-to-head with COL4A6 at Xq22.3, and the two genes share a 
bidirectional promoter region (Khoshnoodi et al., 2008). Mutations in the COL4A5 gene 
cause Alport syndrome (MIM #301050), whereas only partial deletions of the promoter 
region have been reported in patients with Alport syndrome and diffuse leiomyomatosis 
characterized by smooth muscle overgrowth (ATS-DL, MIM #308940). Activation of a 
neighboring gene of the COL4A5/COL4A6 locus has been proposed as a mechanism for the 
smooth muscle overgrowth in ATS-DL (Thielen et al., 2003). Sporadic deletions at the 
COL4A5/COL4A6 locus have earlier been detected in leiomyomas of esophagus (Heidet et al., 
1998), and now in our study. The IRS4 gene, encoding insulin receptor substrate 4, is a 
plausible candidate for smooth muscle overgrowth, since dysregulation of insulin-like growth 
factor signaling has been earlier implicated in leiomyomas (Burroughs et al., 2002). 
Chromosome arm 7q has been shown to display frequent losses in leiomyomas, with a few 
candidate target genes identified earlier (Ligon et al., 2002; Quintana et al., 1998). We could 
show specific rearrangement breakpoints in the CUX1 gene located in the minimally deleted 
region across our tumors. In one tumor, biallelic inactivation by two independent CCR events 
was observed, suggesting that CUX1 is a tumor suppressor. CUX1 functions as a transcription 
factor, regulating expression of DNA damage response genes (Vadnais et al., 2012). At the 
same time of our study, CUX1 was independently reported as a specific target gene for 
haploinsufficient inactivation in acute myeloid leukemias and in uterine leiomyomas 
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(McNerney et al., 2013; Schoenmakers et al., 2013). Disruptions of CUX1 co-occur with 
MED12 mutations and HMGA2 activation as shown by us and others (Markowski et al., 
2012), indicating that CUX1 inactivation is a secondary change in the development of uterine 
leiomyomas. 
Tumors clustered separately according to the alterations of MED12, FH, HMGA2/HMGA1 or 
COL4A5/COL4A6 in the gene expression analysis, with the exception of a single tumor 
displaying the massive chromothripsis, CCND1 upregulation and COL4A5/COL4A6 alteration. 
The clustering has also been confirmed with our recent data including more tumors (Mehine 
et al. unpublished results). Thus, it seems that the development of uterine leiomyomas is 
driven by at least four mututally exclusive molecular pathways having distinguishable global 
expression profiles. Majority of leiomyomas are formed through MED12 mutations (Figure 
10), which seem to lead to development of smaller tumors (Mäkinen et al., 2011b). Tumors 
displaying HMGA2 activation represent the majority of cytogenetically abnormal and large 
leiomyomas (Bulun, 2013) formed through CCRs or simple balanced translocations (Figure 
10). 
 
Figure 10. Model of uterine leiomyoma development. Different mutational mechanisms create 
changes that affect the normal function of myometrial cells. Somatic MED12 mutations drive the 
majority of lesions. The upregulation of RAD51B in MED12 mutated tumors might reflect cells 
responses to replication stress. A substantial proportion arises through complex chromosomal 
rearrangements (CCRs) that impair the control of cell cycle checkpoints and repair of DNA double-
strand breaks, such as rearrangements between the HMGA2 and RAD51B loci. Simple chromosomal 
rearrangements also create similar changes. A less frequent route is inactivation of FH, resulting in the 
tumor development possibly through metabolic stress. 
Sequence analysis was also able to provide definitive evidence for the clonal origin of 
multiple tumors in three patients. Similar phenomenon had also been proposed earlier by 
cytogenetic analyses (Nibert and Heim, 1990; Nilbert et al., 1990). We were able to show that 
subclonal cells from one tumor had disseminated a secondary tumor within a single uterus. 
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Further studies are needed to clarify, what prevents tumor cells from metastasizing, and 
whether cell lineages with a specific genetic background are more prone to seed multiple 
tumors. 
6.4 Identification of tumor susceptibility phenotypes using registry-based 
data (IV) 
Familial aggregation studies of cancer are usually restricted to patients whose family 
members are known. We inferred family relations from the birth municipality and family 
name at birth combinations for all the patients in FCR; thus we were able cover remarkably 
more cases and detailed tumor types than previous comprehensive studies conducted in the 
Icelandic or Utah populations (Albright F Ph et al., 2012; Amundadottir et al., 2004; Goldgar 
et al., 1994). We were able to estimate the familiality of both common and rare tumor types 
by developing the cluster score method. The cluster score ranking highlighted known rare 
cancer predisposition syndromes such as Von Hippel-Lindau syndrome (VHL, MIM #193300) 
and Multiple Endocrine Neoplasia type 2 (MEN2A, MIM #171400, and MEN2B, MIM 
#162300), providing evidence that our method is appropriate for familiality estimation.  
Also tumor types without known predisposition phenotype were featured in the cluster score 
ranking, including Kaposi sarcoma. Thorough genealogy work of the MN-clusters of KS 
patients identified seven families with two first-degree relatives with KS, and a remarkable 
family with five KS cases. These confirmed familial cases of KS represented 70% of the cases 
in the MN-clusters, most of which were high confidence clusters in terms of O/E and CI-low 
values. Thus, it seems that our proportional incidence and statistical significance measures are 
appropriate for identifying clusters with true relatives. The systematic registry-based 
clustering has been performed yearly after the publication of study IV, and one additional 
family with two first-degree relatives with KS has been identified. 
The success of the clustering method owes much to the diversity of family names in Finland 
and to the isolation of villages in the history of the Finnish population. Patients with common 
family names in Finland were less likely to produce statistically significant clusters. Tumor 
types that occur with higher frequency in sibships and in father-child pairs are 
overrepresented in our clusters, because family name at birth is usually inherited from the 
paternal side in Finland. Unfortunately, systematic search for true family relationships from 
NPR is limited to only those patients who have lived in the 1960s or later. Both or one parent 
was found from NPR for only ~15% of patients in the clusters, when this systematic approach 
was tested with selected tumor types.  
Familial relations of the KS cases in N-clusters were not studied thoroughly due to large 
numbers of cases and the slowness of genealogy work. A number of false positives are 
expected among these clusters, although N-clusters are not constrained by municipality 
borders. Therefore, we have now considered dividing the Finnish municipalities into regions 
and performing clustering based on tumor type, birth place regions and family names at birth.  
In addition to KS, small intestine neuroendocrine tumors showed strong familial aggregation 
in our study. High familial risk has been reported in other studies as well (Hemminki and Li, 
2001; Hiripi et al., 2009; Kharazmi et al., 2013), but genetic basis of the predisposition is 
largely unknown. Papillary thyroid adenocarcinoma, chronic lymphatic leukemia, and 
squamous cell carcinoma of lip, all considered here as common tumor types with over 7,000 
registered patients in FCR, showed also high ranking according to cluster score. Interestingly, 
the same cancer sites have high incidence in familial cases who are distantly related to each 
other (more than first cousins), as demonstrated in a study of the Utah population (Albright F 
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Ph et al., 2012). Our method should also be able to detect relatives outside the nuclear family, 
but genealogy work is needed to confirm family relationships.  
We have identified so far 21 familial KS cases, and 74 familial cases have been reported 
elsewhere, mostly in the Jewish population (Almohideb et al., 2013). The Finnish family of 
five KS cases is among the largest families reported to date (Cottoni et al., 1996; DiGiovanna 
and Safai, 1981). HHV8 infection is required for the manifestation of KS, and persons with 
immunodeficiency are at higher risk for KS (Safai et al., 1985). KS incidence and HHV8 
prevalence varies in different populations (Mesri et al., 2010), Finnish showing an average 
standardized KS incidence rate of 0.1-0.2 per 100,000 person-years. As shown in our study, 
the incidence of KS according to municipality of birth varied strongly between Eastern and 
Western Finland, although HHV8 infection seems to be rare in both regions. HHV8 
prevalence should be studied more carefully in order to know whether the uneven distribution 
of cases is due to uneven distribution of HHV8 prevalence or genetic susceptibility in Finland. 
Intrafamilial transmission of HHV8 has been suggested (Mancuso et al., 2011), which may 
explain some of the familial cases observed in our study. The five KS cases in a single family 
had seemingly normal immunity, indicating that HHV8 infection must be accompanied with 
genetic susceptibility to develop tumors in the family.  
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7. Conclusions and future prospects 
Epidemiological and molecular approaches in studies I-IV led to characterization of novel 
susceptibility phenotypes, and genetic background of right atrial isomerism, severe 
intellectual disability, and uterine leiomyomas. 
Study I: RAI was recessively inherited in a family with five affected siblings and healthy 
parents. Positional candidate-gene approach allowed identification of two truncating 
mutations in GDF1, shown to be compound heterozygous in the patients. Similar phenotype 
had been characterized in Gdf1 knockout mice, providing firm evidence that the mutations in 
GDF1 are causative for RAI in the family. We were able to identify multiple healthy 
heterozygous carriers of truncating GDF1 mutations, which bring into question the role of 
heterozygous loss-of-function mutations in GDF1 in congenital cardiac defects as previously 
reported. The proportion and type of GDF1 mutations underlying laterality and congenital 
cardiac defects should be studied in more patients. Screening of GDF1 mutations is feasible 
for molecular diagnosis of RAI at earlier stages of pregnancy than echocardiography, and 
could facilitate genetic counseling for families with a history of laterality defects. 
Study II: A novel autosomal recessive ID syndrome was characterized and an unambiguous 
linkage was found at the 3p22.1-3p21.1 locus displaying a large homozygous region in six 
consanguineous ID patients from four sibships. Whole-genome sequencing pinpointed three 
genes with potentially protein damaging sequence changes as novel candidates for syndromic 
ID. No definite conclusion of the role of the genes could be drawn. Clinical and genetic data 
obtained in this study can be used to identify patients with a similar phenotype elsewhere. 
Further work is obviously needed to show the combined or individual role of the candidate 
genes in the etiology of the autosomal recessive ID syndrome. 
Study III: Complex chromosomal rearrangements resembling chromothripsis were detected in 
uterine leiomyomas by whole-genome sequencing.  Although earlier associated with 
malignant tumors, the massive remodeling phenomenon can also occur in these benign tumors 
and create driver changes that promote leiomyoma growth in sequential fashion. CCRs were 
common in tumors without MED12 and FH mutations, warranting further studies on 
mechanisms underlying CCRs and chromothripsis. Four molecular subgroups driven by 
alterations of MED12, FH, HMGA2/HMGA1 or COL4A5/COL4A6 were characterized, and in 
some patients multiple separate tumors displayed common clonal origin. Leiomyomas with 
distinct biological properties should be studied further to allow personalized treatment of 
patients with more severe symptoms and aggressive tumor growth. 
Study IV: Measures of familiality were successfully derived for both rare and common tumor 
types by utilizing the population based data in the Finnish Cancer Registry. The systematic 
registry-based search for familial aggregation of all types of cancers was able to identify 
familial cases suitable for sample collection, and for further research on underlying genetic 
predisposition. Kaposi sarcoma showed strong familiality, and prevalence of viral and genetic 
predisposition in Finland should be studied further, as an unequal distribution of Kaposi 
sarcoma patients in Eastern and Western Finland was noted. Furthermore, FCR can be used to 
derive sample information for all the patients examined in pathology laboratories, enabling 
genetic studies of the novel susceptibility phenotypes with the advanced genome-wide 
approaches. 
The approaches used in this thesis are applicable to studies of a variety of human diseases. 
The new measurement technologies permit the unbiased genome-wide analyses of variation, 
although large numbers of samples from patients with similar phenotypes are required to 
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determine unequivocally the role of genetic changes in diseases. Availability of patient and 
kinship information is increasing as electronic population-based registries such as NPR and 
FCR were established around 50-60 years ago in Finland, which should be harnessed for 
future studies of genetic epidemiology. Often knowledge of the underlying genetic changes is 
not sufficient, and experimental approaches are needed. There it becomes more and more 
important to understand specific biological systems in relation to disease manifestation. Joint 
effect of environment and genes should also be taken into account in future etiological studies 
of complex diseases.  
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